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To my family 
 
 
 
 
 
 
 
 
 
 
 
 
There is grandeur in this view of life,  
with its several powers, having been originally breathed into a few forms or into one; 
and that, whilst this planet has gone cycling on according to the fixed law of gravity, 
 from so simple a beginning endless forms most beautiful and most wonderful 
 have been, and are being, evolved. 
 
Charles Darwin 
On The Origin of Species, 1st edition 
1859 
 
 
 
   
ABSTRACT 
Natural Killer (NK) cells are members of the innate lymphoid cell (ILC) family and 
take part in the detection and eradication of virus-infected and transformed cells. In this 
thesis, together with my colleagues I have investigated how NK cells and other ILCs 
develop and function during human fetal development, how NK cells are functionally 
regulated (educated) via the activating receptor KIR2DS1, and how NK cells in our 
body are affected during the early phase of an acute viral infection.  
 
Little is known about the ontogeny of NK cells and other ILCs in fetal development. 
The characterization of ILCs has been hampered by their overlapping surface 
phenotypes. In contrast, ILC transcription factor expression is more specific, and by 
combining multicolor flow cytometry analysis of transcription factors and surface 
markers expressed by different fetal ILC subsets, we were able to study and model their 
development and differentiation. All ILC subsets were detected as early as gestational 
week six, and their distribution varied depending on both tissue and gestational age. 
Moreover, putative precursors of NK cells were identified as cells that sequentially lost 
CD34 and acquired CD122, Eomes, CD94/NKG2A, T-bet, and CD16. In addition 
putative CD34+ progenitors of RORγt+ ILCs were identified. 
 
In the second trimester of fetal development, analysis of mature fetal NK cell subsets 
revealed that stage 4 and stage 5 NK cells differed in frequency in fetal organs, and the 
highest NK cell frequency was found in the fetal liver and lung. The vast majority of 
fetal NK cells were NKG2A+, and fetal lung NK cells also frequently expressed killer-
cell immunoglobulin-like receptors (KIR). Interestingly, while NKG2A educated fetal 
NK cells similar to adult NK cells, KIR expression on fetal NK cells was linked to 
hyporesponsiveness, thus contrasting education of NK cells after birth. Nevertheless, 
fetal NK cells were highly responsive to cytokines, as well as to antibody-coated target 
cells, suggesting they may take part in fetal immune responses against in utero 
infections, while remaining tolerant to maternal cells crossing the placenta. 
 
While it is established that NK cells in adults are educated via inhibitory KIRs, it is not 
known how activating KIRs such as KIR2DS1 affects NK cells. By combining 
antibodies against four inhibitory KIRs, NKG2A, and KIR2DS1, we were able to 
interrogate the regulation of NK cells by KIR2DS1. We found that KIR2DS1 single-
positive NK cells exist in vivo, and that the presence of the ligand for KIR2DS1, HLA-
C2, resulted in hyporesponsiveness of such NK cells, thus ensuring self-tolerance. Our 
findings represent the first identification of NK cell education via activating KIR. 
 
The human NK cell response to viral infections is not well understood. To this end we 
employed the live attenuated yellow fever vaccine 17D as an in vivo model of an acute 
viral infection. Our results show that the vaccine primed NK cells, and that less 
differentiated CD57- NK cells dominated the response, which peaked at day 6-10 post 
vaccination. Moreover, KIR expression on NK cells did not affect their response to the 
vaccine, indicating that NK cells expressing self-KIR and non-self KIR contributed 
equally to the NK cell response to the vaccination. 
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1 INTRODUCTION 
Since the dawn of life on our planet, evolution by natural selection has favored species 
that can stay ahead in the arms race for survival and reproduction (1). Smaller 
organisms have evolved ways to hide and survive inside larger plants and animals, such 
as humans. In turn, we and other organisms have evolved defense systems to protect us 
from invaders, and inside our bodies we find a sophisticated immune system that 
protects us not only against foreign invaders, but that also surveys our own cells and 
ensures damaged cells are removed (2).  The immune system involves a multitude of 
cell types and interactions, and in my work I have studied the natural killer (NK) cell, 
and other members of the innate lymphoid cells (ILCs). NK cells are fast responding 
innate lymphocyte capable of detecting and killing virus-infected cells as well as tumor 
cells. In recent years it has also been appreciated that NK cells form a bridge between 
the innate and adaptive arms of the immune system (3). 
 
1.1 FLOW CYTOMETRY 
The phenotype and function of all cells in our body are defined by the receptors 
expressed on the cell surfaces, and what proteins and molecules are present and active 
inside the cells. To learn about cell function and behavior, scientists thus need to obtain 
information about these features, and in particular when studying NK cells, learning 
about the array of receptors determining their phenotype and regulating their function, 
is paramount. 
 
Flow cytometry is a technique central to the work in this thesis, which allows 
immunologists to study immune cells in great detail. It was developed in the late 1960’s 
and was inspired by instruments used at Los Alamos National Laboratories, to count 
and separate particles in nuclear fallout (4, 5). The principle of this technique is largely 
unchanged and briefly works by combining the coupling of a fluorochrome to an 
antibody specific for an antigen expressed by the cell of interest, e.g. the cell surface 
protein CD56 on NK cells. Single-cell suspensions of cells are mixed with such 
antibodies, which saturate and “stain” the cells. These are then analyzed with a flow 
cytometer, where cells are led through laser beams one at the time (Figure 1). The 
fluorochromes are excited when the cell passes a laser beam, and the amount of light 
that is subsequently emitted by the fluorochrome will be proportional to how much 
antibody is present, i.e. how much of the particular antigen is present on the surface (or 
inside) the cell. To extract this information, the emitted photons are converted into 
electrical signals using photomultiplier tubes, and the amount of antigen can then be 
visualized and analyzed with a computer (Figure 1). Thousands of cells can be 
analyzed per second, and the information from many antibodies coupled to 
fluorochromes with different excitation properties can be combined to provide high-
dimensional information about each cell. By collecting information from many cells 
isolated from e.g. the peripheral blood, or from an organ, statistically representative can 
be obtained.  
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When seeking to consolidate the data from experiments with NK cells, during his thesis 
work, Klas Kärre identified a common denominator of cells resistant to NK cell killing: 
resistant cells expressed high levels of a full set of MHC class I (11). Kärre therefore 
postulated that these molecules represented “self-signatures”, and that NK cells 
expressed inhibitory receptors interacting with the MHC class I molecules on these 
cells. NK cells would therefore be activated by the absence of a full set of MHC class I, 
which was presented as the “missing-self” hypothesis (7, 12).  
 
Classical killing of a target cell by an NK cell has since been shown to rely on the 
formation of an immunological synapse, which forms via interactions of receptors on 
NK cells, and ligands on the putative target cell. NK cells degranulate and release 
preformed granules containing perforin and granzymes (13). Most data suggests that 
perforin forms pores in the target cell membrane, and that granzymes then enter the 
target cell where they induce apoptosis (14). Degranulation brings with it the molecule 
CD107a to the surface of the NK cell, and CD107a expression can thus be used as a 
surrogate marker of NK cell degranulation in flow cytometry assays (15, 16). Because 
of their potency as killers, NK cell function is tightly regulated by an array of activating 
and inhibitory receptors, as well as via cytokines that activate or inhibit NK cell activity 
(17). 
 
1.2.1 NK cell receptors 
Killer-cell immunoglobulin-like receptors 
In the decade that followed the postulation of “missing-self” activation of NK cells, the 
sought-after inhibitory MHC class I receptors that would convey this signal were 
identified in mice in the form of Ly49 receptors (18), and in humans as Killer-cell 
Immunoglobulin-like Receptors (KIR) (19, 20). These receptor types are structurally 
different and therefore represent convergent evolution, indicating that they play 
important physiological roles. 
 
KIR genes are found in the Leukocyte Receptor Complex (LRC) on chromosome 19 
and KIRs with an “L” in their name contain a long cytoplasmic tail with 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs), thus making such receptors 
inhibitory. KIR with shorter cytoplasmic tails (“S”) instead have charged amino acids 
in their membrane region, allowing them to interact with DAP-12, a signaling molecule 
conveying activating signals via immunoreceptor tyrosine-based activation motifs 
(ITAMs) (21). The KIR gene family is highly polymorphic and polygenic, and KIR 
gene combinations carried by different individuals can be separated into more than 40 
haplotypes, based on their KIR gene content (22). Two main haplotypes have been 
identified; haplotype A have only inhibitory KIR, with the exception of KIR2DS4, 
whereas haplotype B carry both inhibitory and activating KIR genes. Because we 
inherit half our genes from each parent, it is possible to carry haplotype A/A, A/B, or 
B/B. Haplotypes can also be divided based on presence of centromeric and telomeric 
gene-content motifs (23). 
 
Thirteen KIR genes have been found expressed as proteins, and ligands for seven of 
them have so far been identified (Table 1). Adding to their diversity is a high 
variability in copy numbers of individual KIR genes (24), which translates into higher 
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frequencies of NK cells expressing KIRs with more gene-copies present (24-26). The 
expression of KIR2DL1 and KIR2DS1, which both bind to HLA-C2 (27), is of 
particular interest for Paper III. However, also the binding of KIR3DL1 to HLA-Bw4 
(28) and KIR2DL2/3 to HLA-C1 (and some HLA-C2) (29) are relevant for Papers II-
IV, and the role of KIRs in education of NK cells will be discussed in detail below. 
Another inhibitory receptor encoded on the same chromosome as KIR also expressed 
by NK cells is LILRB1 (also known as ILT2). It binds to HLA-A, B, C and G 
molecules as well as virus-encoded proteins (30, 31). 
 
 Known HLA class I ligands   
KIR A3 A11 Bw4 C1 C2 G 
3DL1       
3DS1       
3DL2       
3DL3       
2DL1       
2DL2/3     Some alleles  
2DS1       
2DS2       
2DS3       
2SD4    Some alleles Some alleles  
2DS5       
2DL4       
2DL5       
Table 1. Expressed KIR genes and known KIR-ligands (23) 
 
KIR gene expression is regulated so that KIRs are expressed in a variegated manner. 
The molecular mechanism for this involves epigenetic regulation via methylation of 
promoter regions of KIR genes, and a molecular switch that regulates transcription of 
KIR via bidirectional promoters (32). This multifaceted system endows humans with 
complex and unique KIR repertoires, comprising NK cells expressing 0, 1, 2 or more 
KIRs. Expression of KIRs has been determined to largely follow the product rule 
(%KIR-A+KIR-B+ = %KIR-A+ x %KIR-B+) (33). At steady state, the presence of KIR-
ligands does not affect the frequency of NK cells expressing a particular KIR. This has 
been described both on cord blood NK cells (34), and in adult peripheral blood NK 
cells (35). However, deviations from the product rule have been found, and KIR 
acquisition probability increases with the number of KIRs already expressed by a cell 
(35). Moreover we have shown that the NK cell KIR repertoire is affected by 
cytomegalovirus (CMV) infection (36), which is discussed more below.  
 
As a consequence of the great variability in the KIR/HLA system, KIR/HLA 
combinations have been associated with the risk of acquiring and progressing in 
diseases of autoimmunity, cancer, viral infections, as well as pregnancy related 
disorders (37, 38). Most studies rely only on genetic data, but with new tools to study 
NK cell phenotypes, both with respect to expression of KIRs, and other receptors and 
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intracellular proteins, more mechanistic insights into the role of NK cells in different 
disease settings can likely be gained. 
 
CD94 and NKG2A/C 
Chromosome 12 carries another gene cluster encoding NK cell receptors, which is 
called the natural killer complex (NKC) (39). Two heterodimeric NKC-encoded 
receptor pairs are CD94:NKG2A and CD94:NKG2C. They both recognize the non-
polymorphic HLA-E (40), but whereas NKG2A confers inhibitory signals (41), 
NKG2C is activating (42). HLA-E surface expression displays leader-peptides from the 
classical HLA class I molecules. As a consequence, HLA-E expression on a cell can 
reflect how much HLA class I is produced overall, whereas inhibitory KIRs monitor 
expression of individual HLA alleles. NK cell regulation via CD94/NKG2A/C and 
KIRs therefore theoretically make up a sophisticated system to sense changes in both 
quantity and quality of HLA expression on cells, which often occurs in disease, as 
viruses or tumor cells seek to avoid detection by the adaptive immune system (43). 
 
Additional NK cell receptors 
NK cells can be said to be “unleashed” when confronted with a target cell lacking 
inhibitory ligands, because at steady state the inhibitory signals from KIR and NKG2A 
are dominant. This was part of Kärre’s original postulate, stating that also activating 
NK cell receptors must be expressed on NK cells, whose signaling becomes dominant 
in the “missing-self” situation (7). Indeed, many activating receptors have been 
identified, including the aforementioned NKG2C and activating KIR. We recently 
reviewed the current literature on activating KIR (Ivarsson et al. invited review), and 
their role in education of NK cells is detailed in Paper III and below. Moreover, NK 
cells express many activating NK cell receptors that interact with non-HLA ligands 
(44). 
 
The first activating NK cell receptor to be identified was CD16 (45), which is 
expressed by the majority of peripheral blood NK cells. It binds with low affinity to the 
Fc-domain of IgG, and allows NK cells to perform antibody-dependent cellular 
cytotoxicity (ADCC) (17). CD16 signals through homo- or heterodimers of FcRγ and 
TCRζ, which contain ITAM motifs. NK cell activity mediated via CD16 adds another 
dimension to NK cell specificity, since it allows binding to target cells coated with 
antibodies produced by B cells, thus making NK cells an effector-component of the 
adaptive immune system. Most activating NK cell receptors are expressed by virtually 
all NK cells, including 2B4, DNAM-1, NKG2D, NKp30, NKp46, and NKp80 (46), 
generating an array of receptors with different ligands. Many of these ligands (e.g. the 
2B4 ligand CD48) are expressed by healthy cells in the body, facilitating adhesion of 
NK cells to putative target cells. Other ligands are induced on stressed cells such as 
tumor cells and on virus-infected cells. These include MICA/B and ULBP proteins that 
bind to NKG2D (47). NK cells also express CD95L/FAS-ligand, and IFN-γ produced 
by NK cells can induce CD95/FAS expression on target cells, which in turn make these 
cells susceptible to FAS-mediated killing by NK cells (48).  
 
NKp30 and NKp46, together with the activation-induced NKp44, make up the Natural 
Cytotoxicity Receptors (NCRs) (39). Ligands for NKp30 (B7-H6) (49) and NKp44 
(MLL5) (50) have both been identified on tumor cells. NKp46 has also been suggested 
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to mediate recognition of tumor cells, but a ligand has not yet been identified. Both 
NKp46 and NKp44, have also been associated with binding to hemagglutinin of several 
viruses (51). Moreover, the relatives of NK cells, the non-NK ILCs, which are 
discussed below, can also express the NCRs (52). Together with the inhibitory 
receptors sensing MHC class I expression, the array of activating receptors enables NK 
cells to detect a wide range of target cells (46).  
 
From the perspective of an immunologist, the most important receptor on human NK 
cells is CD56. Ironically, its importance is not coupled to a function, because this is not 
known, but CD56 has since long allowed immunologists to identify human NK cells 
(53). Moreover, expression intensity of CD56 separates peripheral blood NK cells into 
two populations, CD56bright and CD56dim, and it was early on suggested that the latter 
differentiate from the former (54). CD56bright NK cells uniformly express NKG2A, lack 
CD16, and are the dominant NK cell subset in lymphoid organs (55). CD56dim NK cells 
are CD16+ but diverse in their expression of NKG2A/C and KIRs (17). A CD56superbright 
NK cell subset has also been identified in the uterus (56), and a growing body of data 
suggests they exhibit unique functions (57, 58). Whether these tissue-resident NK cells 
represent unique NK cell types, or whether peripheral blood NK cells and tissue-
resident NK cells are developmental stages of one type of NK cells, is not known but is 
currently a hot topic of research. Importantly, other members of the recently identified 
innate lymphoid cells (ILCs) can also express CD56, and it is thus not as specific to NK 
cells as initially believed (59).  
 
NK cell regulation via cytokines 
In addition to being regulated via cell-cell interactions, NK cell activity is regulated via 
cytokines. The cardinal interaction partners include macrophages and dendritic cells 
(DCs), which can produce IFN-α, IL-12, IL-15 and IL-18. These cytokines have 
priming effects on NK cells, and lead to a lower activation threshold, stronger response 
against target cells, as well as the production of IFN-γ and TNF-α (60, 61). In addition, 
chemokines including MIP-1α/β, RANTES, and GM-CSF are also produced by NK 
cells (62). Cytokines dampening NK cell responsiveness include TGF-β (63), and this 
provides a way for the immune system to also inhibit NK cell activity using soluble 
factors.  
 
Importantly, cytokine stimulation alone, without cell-cell interactions, can activate NK 
cells and lead to the production of IFN-γ and other factors by NK cells. CD56bright NK 
cells have traditionally been considered more sensitive to cytokine stimulation and 
geared towards cytokine production compared to CD56dim NK cells, which instead are 
described as more cytotoxic (60). Importantly however, CD56dim NK cells, but not to 
the same extent CD56bright NK cells, produce cytokines when stimulated with target 
cells (61). The IFN-γ produced by NK cells can contribute to the inflammatory 
response, and studies have revealed that in the murine lymph node (LN), IFN-γ is 
important for polarization of T cells to Type 1 helper T cells (64), thus showing that 
NK cells can influence the adaptive immune response. A similar role in tuning of T cell 
function by NK cells has been found in murine other virus infection models (65, 66). 
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1.2.2 NK cell education 
Central to regulation of NK cell function, and to the work in Paper II-IV, is the 
concept of NK cell education (67). To maintain self-tolerance while also being able to 
detect aberrant cells, NK cells must know when to become activated. This intuitively 
requires the expression of at least one self-MHC class I receptor, thus inhibiting the NK 
cell in a normal self-situation, and indeed this notion was supported by initial studies 
investigating NK cell regulation (33). Surprisingly however, mice and humans lacking 
MHC class I molecules (constantly “missing” inhibitor self-signals to NK cells) were 
found to have normal number of NK cells. Such NK cells were however 
hyporesponsive, indicating that absence of MHC class I is not sufficient to trigger NK 
cells, but rather that NK cells are educated to detect “missing-self” (68).  
 
Continued investigation of NK cell regulation via MHC class I revealed that murine 
NK cells indeed required active engagement by inhibitory Ly49 with its ligand for the 
NK cell to become functionally active, or “licensed” (69). Shortly after, using 
multicolor flow cytometry and the CD107a degranulation assay, Anfossi and 
colleagues found evidence of the same phenomenon in human NK cells (70). By 
studying NK cell subsets defined based on co-expression of inhibitory KIRs, and 
NKG2A, the authors compared the functional response from KIR+NKG2A+ and KIR-
NKG2A- NK cell subsets, following stimulation with the commonly used HLA class I 
negative target cell line K562. NK cells expressing KIRs and NKG2A responded on 
average twice as good as cells lacking KIRs and NKG2A. This feature was cell-
intrinsic since the same difference in response was seen when the cells were stimulated 
with antibodies via CD16. The authors went on to show that NK cells expressing only 
KIR with cognate ligand present (e.g. KIR2DL1/HLA-C2) were functionally educated, 
and responded more than KIR- NK cells, or KIR2DL1+ NK cells in a donor lacking 
HLA-C2. The implication of this was that human NK cells expressing inhibitory KIR 
together with the cognate ligand results in an educated NK cell, licensed to kill cells 
lacking the cognate ligand. These results were extended to include KIR3DL1 and 
HLA-Bw4 (71), and were also corroborated by Yawata and colleagues who also 
showed that NKG2A alone licenses human NK cells (72). An alternative type of NK 
cell education has been suggested from other studies, where NK cells are postulated to 
be disarmed by chronic stimulation via activating receptors, in the absence of self-
receptors (73).  
 
A mechanism for how inhibitory receptors mediate the education of NK cells has not 
been identified. However, studies indicate that signaling through ITIMs can generate 
both a weaker signal that efficiently blocks initiation of activating signals, and a 
stronger signal that is needed to generate a licensed state (74). Adoptive transfer 
experiments with mice have also found that the licensing of an NK cell is reversible 
(75, 76). This can be explained by a model where NK cells are constantly 
quantitatively and qualitatively tuned by their surrounding MHC class I, leading to a 
dynamic range of education levels, tuned by MHC class I like a rheostat (77). Such a 
model of education is compatible with both licensing and disarming, where the rheostat 
can be seen as being tuned up or down, respectively. According to the rheostat model, 
NK cells are not activated by a gradual or slow loss/change of MHC class I (such as in 
an adoptive transfer experiment in mice, or hematopoietic stem cell transplantation in 
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humans), whereas a relatively sudden loss or down-regulation (i.e. a virus- or tumor 
transformation) will be detected and will unleash appropriately tuned NK cells (46). 
 
Interestingly, NKG2A-KIR- NK cells cultured with IL-2 without accessory cells 
acquired both NKG2A and inhibitory KIR, which in turn licensed NK cells (78). 
Whether such NK cell differentiation and education takes place in vivo remains to be 
determined, but may take place in lymph nodes during immune responses. Importantly, 
non-licensed NK cells are functional when stimulated with cytokines, or via CD16. In 
fact, it is possible that such NK cells can be the main responders to a virus infection 
where MHC class I expression is retained on infected cells, since they would not be 
inhibited, but could readily be stimulated by cytokines induced by the immune 
response, and sense stress ligands up-regulated by infected cells (73). Indeed, non-
licensed NK cells have been found to control mouse CMV infection (however, no 
analysis of NKG2A on these cells was performed) (79). These authors also speculate 
that non-licensed NK cells used in cancer therapy might be beneficial, since they will 
not be inhibited by HLA, but will sense stress ligands on tumor cells.  
 
Intuitively, expression of activating KIR2DS1 on NK cells in the absence of other 
inhibitory receptors, and in an individual where the cognate ligand HLA-C2 is 
expressed, could lead to an autoreactive situation. Prior to our study in Paper III, it 
was not known whether such NK cells were selectively low in frequency or absent, or 
whether they do exist in vivo but are differentially educated to ensure tolerance.  
 
1.2.3 Models of NK cell development 
NK cells are lymphocytes and as such they derive from CD34+ hematopoietic stem 
cells (80). In vitro differentiation studies using CD34+ cells isolated from adult bone 
marrow (81), liver (82), secondary lymphoid organs (83), peripheral blood (83), cord 
blood (84), fetal liver (85), and fetal gut (86), have been found to contain CD34+ cells 
with the potential to become NK cells, but that also could develop into other 
lymphocytes including B and T cells.  
 
To date, no CD34+ progenitor cell that only differentiates into NK cells has been 
described. However, careful analysis of developmental stages of human NK cells led 
Freud and colleagues to propose a model of NK cell development (87), according to 
which CD34+ cells co-expressing CD45RA and integrin β7 preferentially develop into 
NK cells, although this cell population still possessed T/B/DC differentiation potential. 
Such CD34+ cells are first CD117 (c-kit) negative stage 1 NK cells, and subsequently 
acquired CD117 to become stage 2 NK cells (Figure 2). Loss of CD34 and expression 
of CD161, CD117, and CD127 marked stage 3 NK cells according this model. NK 
cells rely on IL-15 for their development and NK cell numbers are dramatically 
reduced in patients carrying mutations relevant for its binding and signaling (88, 89). 
Studies using humanized mice have further shown that trans-presented IL-15 (in 
complex with its receptor IL-15Rα) has a superior effect on NK cell development and 
differentiation (90). CD122 (IL-15Rβ) was suggested to be expressed already at stage 2 
NK cells, and marked stage 3 NK cells, although it was not readily detectable by flow 
cytometry at these stages (87). Stage 3 NK cells were also described as committed, 
immature NK cells, since they readily acquired CD94 in culture with IL-15, and could 
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not develop into T or B cells. Acquisition of CD94/NKG2A marked stage 4 NK cells, 
the first mature NK cell stage, which corresponds to CD56bright NK cells in blood and 
tonsils (87).  
 
Studies on secondary lymphoid organs such as lymph nodes suggested that CD34+ NK 
cell progenitors seed these organs, and where subsequent NK cell differentiation takes 
place (91). Importantly, cells that had reached a particular stage could not be 
differentiated backwards to a lower stage and when published in 2006, this model was 
satisfying and represented a big leap in our understanding of human NK cell 
development. However, recent years have seen the discovery of other innate lymphoid 
cells, alongside NK cells, and the original model of NK cell development, in particular 
the definition of stage 3 NK cells, has been found to be in need of updating (92).  
 
 
Figure 2. Model of NK cell development and differentiation based on studies by Freud et al. (87). 
 
1.2.4 Innate lymphoid cells 
Other innate lymphoid cells (ILCs) that share a developmental origin with NK cells 
have been identified in recent years. In contrast to NK cells, these cells are not 
dependent on IL-15 for their development, but instead rely on IL-7, and express the IL-
7α receptor (CD127). The roles these ILCs play in health and disease is starting to be 
unraveled but it is my intention here to primarily discuss them in the context of their 
developmental relationship to NK cells. A nomenclature with three groups of ILCs has 
been proposed (93). These are defined based on the functional characteristics and 
transcription factor expression of the different ILCs (Figure 3). Group 1 ILCs perform 
type 1 immune functions, and contain T-bet+ IFN-γ producing ILC1, and Eomes+/T-
bet+ NK cells (that uniquely among ILCs also can be cytotoxic). Group 2 ILC contain 
ILC2s that produce type 2 cytokines, and group 3 ILCs contain RORγt+ Lymphoid 
Tissue inducer (LTi) cells and ILC3s (59). 
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Figure 3. Innate lymphoid cell (ILC) family overview. ILC functional characteristics that have been 
described for human ILCs are illustrated. 
 
Lymphoid Tissue-inducer cells 
The first non-NK ILC to be discovered was the LTi cell. In the late 1990ies, Mebius et 
al. identified a Lin-CD4+CD127+ lymphocyte in developing lymph nodes during murine 
embryogenesis; the LTi cell (94). These cells was among the first hematopoietic cells 
to develop during murine fetal development, and evidence suggest it interacts with 
mesenchymal cells to initiate lymphoid structure formation including lymph nodes and 
Peyer’s patches (95). Upon culture with IL-2, a fraction of the murine LTi cells were 
found to give rise to cells with NK cell features (94). Subsequent studies revealed that 
LTi cells rely on the transcription factor RORγt (96) for their development. Moreover, 
both the generation of lymphoid organs (i.e. the presence of LTi cells), and the 
development of peripheral NK cells were found to rely on the transcription factor ID2 
(97). These data thus supported a model where LTi cells potentially represented an 
intermediate stage of developing NK cells, and both these cell types derived from an 
ID2-dependent precursor.  
 
Although quickly hypothesized to exist, the human LTi cell counterpart took more than 
a decade to identify (98). Similar to mouse LTi cells, these were found in the fetal 
mesentery where lymph nodes develop, and LTi cells expressed CD127, contained 
RORγt mRNA, and also expressed two markers associated with NK cells, namely CD7 
and CD161. The cells produced IL-17 and IL-22, and just as in mice, human LTi cells 
could give rise to NK-like cells, thus suggesting that NK cells develop through a RORγt 
mRNA-expressing LTi-stage, prior to becoming mature NK cells (98). Importantly 
however, the NK cell-like cells derived from human LTi cells expressed only some 
features of NK cells, including NCRs and CD56. But in contrast to peripheral blood 
NK cells, they expressed no perforin, CD94 or NKG2D, and still retained CD127 and 
RORγt mRNA. Notably, cells with LTi cell-features were also found in adult murine 
lymph nodes. Using an infection model that generated immune responses that 
destroyed the lymph node architecture, RORγt+ LTi cells were found to significantly 
shorten the time for restructuring the lymph node architecture post infection (99).  
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ILC3 
During the same time-period as the human LTi cell was defined, lymphocytes defined 
as RORγt+NKp46+NK1.1-CD127+ were described in adult murine gut. These 
phenotypically LTi-like cells produced IL-22, but not IFN-γ, and did not contain 
perforin (100). Another group also described that similar cells could produce IL-17, as 
would be predicted by their expression of the Th17 associated transcription factor 
RORγt (101). A human IL-22 producing NK-like cell, referred to as NK-22, was also 
found in the gut and secondary lymphoid organs (102). In line with their capacity to 
produce IL-22, they contained RORγt mRNA. Not long after, with the advent of an 
anti-RORγt antibody for flow cytometry, using tonsil cells, it was revealed that “true” 
stage 3 NK cells (CD34-CD94-CD117+CD161+) do not express RORγt or CD127, 
which however are expressed by LTi cells, and LTi-like NCR+ cells (now called 
ILC3s) (103). The same lineage separation based on transcription factor RORγt was 
also shown in mice using transgenic reporter mice (104), and have since been 
corroborated by in vitro differentiation studies of NK cells and RORγt+ ILC (105). This 
latter study also found that similar to subsets of functional T cells, NK cells contained 
mRNA for transcription factors Eomes and T-bet. Together the studies of LTi cells and 
ILC3s have revealed that NK cells, and RORγt+ ILC share a common progenitor cell 
and rely on ID2 for their development (59). Moreover, in contrast to LTi cells and 
ILC3s, NK cell development does not rely on RORγt, but instead involve transcription 
factors Eomes and T-bet. These two latter transcription factors will be discussed more 
in detail below. 
 
More recent studies of ILC3s have revealed these cells can be both beneficial and 
detrimental to intestinal mucosal health (59). NCR+ ILC3s produce IL-22 in response 
to IL-23 and IL-1β stimulation, and both studies in humans and mice indicate that 
ILC3-derived IL-22 promotes intestinal integrity in the gut, and tissue integrity in the 
lungs. However, NCR- ILC3s can produce proinflammatory IL-17, leading to 
immunopathology (106). The regulation, origin and physiological roles of these cells 
are currently areas of intense research. Not long ago it was shown that similar to NK 
cells, ILC3s are regulated via surface receptors in addition to cytokines. Triggering of 
NKp44 on tonsil ILC3s resulted in production of TNF-α, whereas cytokine stimulation 
with IL-23 and IL-1β resulted in IL-22 production (107).  
 
ILC2 
At the time of identification of stage 3 NK cells as RORγt-, another CD127+ innate 
lymphoid cell was identified in parallel by three groups in mice, which was called 
nuocyte (108), natural helper cell (109), and innate type 2 helper cell (110). This IL-5 
and IL-13 producing population of cells is present in murine gut and lungs, where 
studies have indicated important roles for helminth parasite expulsion, and tissue repair, 
respectively (111). A cell type with similar function has also been identified in both 
fetal and adult humans (112). Just like stage 3 NK cells and RORγt+ ILC, these cells 
express CD161, but can also uniquely express the prostaglandin receptor CRTH-2. 
However, they lack CD56 and other NK cell markers, and do not rely on RORγt for 
their development (113, 114). Instead, ILC2s express high levels of transcription factor 
GATA-3 and RORα, which is needed for their development and function both in 
humans and in mice (113, 114). 
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ILC1 
The most recent ILC subtype to be identified is the ILC1, which completed the mirror 
image that ILCs represent in relation to functional T helper cell subsets (59). ILC1s are 
RORγt-T-betdim and were found in high frequencies in inflamed human gut, and 
produced IFN-γ in response to IL-12 stimulation (115). Moreover, the same group 
showed that ILC1s could be generated from RORγt+ fetal gut ILCs cultured with IL-12 
and IL-18, suggesting plasticity between ILC3s and ILC1s. Notably, Fuchs et al. also 
reported the presence of a mucosal-associated, intra-epithelial ILC1, which expressed 
CD103+NKp44+ (116). Similar to the previous ILC1s, these cells expressed 
intermediate levels of T-bet, and produced IFN-γ when stimulated with IL-12 and IL-
15. Interestingly however, these cells were CD127-CD56+, and contained Eomes 
mRNA at levels similar to NK cells, and their distinction from tonsil-resident NK cells 
is therefore somewhat unclear. Nevertheless, similar to the other ILC types, ILC1s 
represent a highly interesting topic of research. 
 
Compared to other the B cell and T cell fields of immunology research (and except for 
NK cells) the ILC field is in its infancy, and the phenotype of ILCs in health and 
disease is just starting to be investigated. However, it is evident from the amounting 
murine and human studies that these cells are important for many aspects of normal and 
disease-related physiology. With knowledge of what transcription factors different ILC 
subtypes rely on for their development and function, and in light of the co-expression 
of many surface-markers on ILCs; we reasoned it might be advantageous to analyze 
ILCs based on both transcription factor and surface-marker expression. To this end, we 
developed and applied flow cytometry-based analysis of transcription factors and 
surface antigens of ILCs, which we believe will allow more confident identifications of 
human ILC subpopulations in general, and identification of NK cell developmental 
stages in particular (Paper I). 
 
1.2.5 NK cell differentiation  
NK cells that have acquired CD94/NKG2A, and have reached stage 4 in the 
development model, represent CD56bright cells in the blood (117). According to the 
model, this is the first stage of NK cells containing cytotoxic molecules including 
granzymes and perforin, and capability to produce IFN-γ. With antibodies specific 
against transcription factors, the expression of Eomes and T-bet have also been 
identified in CD94+ NK cells (107). These proteins have been implicated in the 
regulation of the expression of the aforementioned cytotoxic molecules, as well as IFN-
γ, both in T cells (118) and NK cells (119). Studies of mouse NK cell development 
indicated that T-bet+ NK cells develop first, and only later does an Eomes+ NK cell 
population arise (120). The expression of Eomes and T-bet proteins in relation to 
human NK cell development has however not been investigated, and is one of the 
topics of Paper I. 
 
In pioneering work using flow cytometry to study human NK cells, Nagler and 
colleagues identified three NK cell subsets; CD16-, CD16dim, and CD16bright NK cells in 
peripheral blood (54). Functional analysis of the subsets indicated that the increase in 
CD16 expression correlated with NK cells becoming more cytotoxic, and also with loss 
of proliferative capacity in response to cytokines. Moreover, the CD16- cells were 
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CD56bright, whereas the CD16+ were mainly CD56dim, and the authors suggested that 
together these features might indicate that NK cells differentiate from CD56bright to 
CD56dim (54). A CD56brightCD16+ NK cell population with intermediate functional 
characteristics has also been described by Béziat and colleagues (121). In the context of 
the NK cell development model introduced previously, CD56dimCD16+ NK cells are 
referred to as stage 5 NK cells (122) (Figure 4). CD56bright NK cells uniformly express 
NKG2A, whereas CD56dim NK cells contain both NKG2A- and NKG2A+ cells (40, 
72), which together suggested that NKG2A could be lost during NK cell 
differentiation. This notion was indeed corroborated by analysis of NK cells in the 
recipients of hematopoietic stem cell transplantations, where NK cells were first 
NKG2A+, and only later started loosing NKG2A expression, and gaining KIR 
expression on subsets of NK cells (123, 124).  
 
 
Figure 4. Model of mature NK cell 
differentiation. 
 
 
Cells that have undergone divisions have shorter telomere lengths, and three groups in 
parallel showed that CD56dim cells have shorter telomere lengths than CD56bright cells 
(125-127). It was also demonstrated that CD56bright cells could acquire both CD16 and 
KIR when cultured with cytokines in vitro (125). Interestingly, the efferent lymph 
(from paracortical/follicular hyperplasia patients) was found to contain intermediate 
levels of KIR+ and CD16+ NK cells, as compared to matched lymph node NK cells and 
peripheral blood NK cells, thus suggesting that CD56bright NK cells can differentiate in, 
and CD56dim NK cells emanate from the lymph node, and circulate to the peripheral 
blood (125). Moreover, the acquisition of CD16 and KIR has also been corroborated 
using humanized mice, where also trans-presentation of IL-15 was found important for 
the differentiation of CD56bright to CD56dim NK cells (90). As introduced above, NK 
cells can express 0, 1, 2 or more KIRs. By analyzing the co-expression of NKG2A and 
four inhibitory KIRs, the number of KIRs expressed by an NK cell correlated with a 
lower probability of co-expressing NKG2A, indicating that as NK cell differentiate 
they loose NKG2A and gain more KIRs (128) (Figure 4). One interpretation of this, in 
relation to licensing of NK cells, is that NK cells start as NKG2A+ and acquire one or 
more KIR, and subsequently down regulate NKG2A (which entails a great loss of 
inhibitory control) only when tolerance via self-HLA class I is ensured by the KIR(s) 
expressed (129). 
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The next step in the investigation of CD56dim NK cell differentiation was inspired by 
studies on T cells and NK cells in the context of HIV infection, where CD57 had been 
identified as a marker of a differentiated subset, less capable of proliferating than other 
subsets (130). Analysis of CD57+ stage 6 NK cells in healthy individuals led three 
groups, including our own (131), to conclude that expression of CD57 indeed marks a 
terminally differentiated NK cell, more likely to express KIR, and less likely to express 
NKG2A (132, 133) (Figure 4). In parallel, other groups showed that also CD16 (121), 
CD62L (134), and CD94 (135), could be used to identify functionally distinct 
differentiation stages of NK cells (136). We also showed that acquisition of CD57 is a 
process uncoupled from NK cell education (131).  
 
Fetal NK cells 
In mice very few mature NK cells are present before birth (137), and this has been 
attributed to effects afforded by TGF-β in fetal and newborn mice (138). In contrast, 
functional human NK cells have been found in first trimester fetal organs (139, 140). 
Moreover, later in gestation, these cells exhibit features of differentiated NK cells, 
including functional CD16 (140) and expression of KIR (141). A study of fetal NK 
cells in relation to the data obtained on adult NK cell differentiation had however not 
been performed. Moreover, it was not known how fetal NK cells expressing NKG2A, 
KIR and CD16 are regulated. To this end, in Paper II we applied the stage 4 to stage 6 
model of NK cell differentiation on cells isolated from second trimester fetal organs, 
and characterized the differentiation and functional regulation of fetal NK cells.  
 
1.2.6 NK cells in virus infections 
Following their initial identification as potent killers of tumor cells, type I interferons 
were also found to activate NK cells, which implicated NK cells in innate immune 
responses against pathogens (142). One clear example of the importance of human NK 
cells came from a case report of a patient lacking NK cells, who suffered from severe 
herpes virus infections (143). Studies in both mice and humans have subsequently 
shown that NK cells provide important initial control of viral replication and spread, 
and an important regulatory role in the shaping of the adaptive immune response. Early 
in a virus infection, dendritic cells (DCs), macrophages, and/or virus-infected cells 
produce factors that affect NK cells (144). DC subsets produce IFN-α and IL-12, and 
trans-present IL-15 to NK cells (144-146), and IL-18, released from DCs and 
macrophages (147), also stimulates NK cells. Depending on the combinations of 
cytokines present, this may lead to NK cell proliferation, activation, and/or production 
of IFN-γ and TNF-α (60, 61). These factors can in turn activate DC and promote Th1 T 
cell polarization. In the periphery, NK cells can also kill immature DC, whereas mature 
DCs are protected from killing via high expression of inhibitory ligands (148). As 
mentioned in the previous section, activation via the DC/macrophage derived cytokines 
also lowers the threshold of activation for NK cells interacting with tumor targets (61).  
 
Arms race between viruses and their hosts 
Viruses have evolved mechanisms to avoid detection by the immune system, which 
allows virions to be produced before the infected cell is detected and eliminated by the 
immune system (2). This has led to an evolutionary arms race between virus-mediated 
mechanisms, and immune mechanisms. Virus-infected cells seek the attention of the 
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immune system by presenting viral peptides on HLA class I and II molecules. CD8+ T 
cells can detect HLA class I presenting pathogen-derived peptides, and kill the infected 
cell, which has promoted viral adaptations that tamper with HLA class I presentation, 
thusly avoiding detection by T cells. However, this loss/change of HLA class I 
molecules instead risks making the virus-infected cells visible to NK cells, as our 
immune system possibly has “counter-evolved” to still cope with the virus. To avoid 
this, the viruses have in turn evolved proteins such as the CMV-encoded UL18 (149), 
which act as decoy ligands for inhibitory NK cell receptors. Infected cells also 
upregulate ligands for activating NK cell receptors, again making themselves visible to 
NK cells. Such ligands include the aforementioned NKG2D ligands ULBPs and 
MICA/B. However, also here viruses such as CMV have adapted and express proteins 
that block such stress ligands from reaching the cell surface (149). Yet other activating 
NK cell receptors implicated in detection of infected cells include NKp44 in HIV 
(150), and NKp46 that binds to hemagglutinin on cells infected with influenza virus 
(151). Other ligands for activating NK cell receptors are likely to be found as new 
techniques and methods are developed (142).  
 
In summary, humans and other mammals are constantly at war with viruses, which 
have evolved ways to avoid detection by the cells of the immune system, and the 
immune systems of animals have responded by evolving protective mechanisms. Many 
such arms races have been going on for millions of years, and it has left imprints both 
in the viral genomes, and in the immune cells of mammals. For instance, CMV 
dedicates a large part of its genome to genes encoding proteins involved in immune 
evasion (152), and in certain mouse strains, the Ly49H receptor seems to have evolved 
solely to detect the m157 CMV protein present on from CMV-infected cells (153, 154), 
and in humans, we have found that CMV infection imprints on the NK cell KIR 
repertoire (36).  
 
Studies of human NK cells in virus infections 
Human NK cell immune responses to virus infections are hard to study and often by 
necessity rely on samples collected after symptom debut. As a consequence, the NK 
cell immune response has likely already taken place, and potentially subsided. 
However, colleagues at our center obtained samples from patients recently diagnosed 
with acute hanta virus infection, and a fast expansion of NK cells in response to the 
virus was found. These expanded cells were NKG2C+CD57+self-KIR+ NK cells that 
persisted for months in the patients (155). Interestingly, they were seen only in CMV+ 
individuals, suggesting potential reactivation of CMV. Indeed, NKG2C+ NK cells had 
previously been shown to expand in the context of CMV-infected fibroblasts (156).  
 
Along the same lines, in analysis of cells from recipients of bone marrow transplants, 
individuals who reactivated CMV also showed an expansion of NKG2C+CD57+ NK 
cells, similar to that seen in the hanta virus infection (157). Finally, we recently used 
longitudinal samples collected from children prior to and after their CMV 
seroconversion (36). These data showed that CMV infection skewed the NK cell 
repertoire towards more NKG2C+CD57+self-KIR+ NK cells (36). Together these 
studies clearly indicate that just as CMV (and other viruses) has adapted to our immune 
system, CMV infection affects the human NK cell repertoire. Whether these expanded 
NK cells are beneficial or not remains to be determined, and will likely depend on what 
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setting they arise in. Clearing of CMV reactivation in patients lacking B and T cells has 
however been positively correlated with expansions of NK cells, suggesting that the 
expanded NK cells are beneficial for virus control (158).  
 
As previously touched upon, another role played by NK cells is in the shaping of the 
adaptive immune response. In a murine lymphocytic choriomeningitis virus (LCMV) 
infection model, virus-induced cytokines activated NK cells, which interacted with 
CD4 and CD8 T cells to regulate the outcome of the infection. This effect was found 
to be positive or negative, depending on the dose of virus used by the authors (65). In 
another recent study from the same group, NK cells were depleted at different time-
points during the course of the same virus infection, and this also had different 
outcomes (159). Together these studies suggested that NK cells could act as “master-
regulators” of the T cell response to this particular virus-infection. TGF-β has also 
been found important for NK/T cell cross-talk, and blocking TGF-β signaling in NK 
cells (but not in DCs) resulted in increased IFN-γ production, which subsequently led 
to Th1 T cell polarization, and more efficient clearing of Leishmania infection (160).  
 
In summary, studies indicate that interaction between NK cells and T cell subsets are 
possibly important factors to consider both for vaccine development, and in treatment 
of acute and chronic viral infections. The interaction between NK cells with T cells in 
human settings has not been studied in detail, nor is it known whether other virus 
types induce similar imprints on the NK cell repertoire as those discussed above. We 
used yellow fever virus vaccination, a live attenuated virus, as a model of an acute 
viral infection, and characterized both the NK cell responses (Paper IV), and the T 
cell response (Paper IV) and reference (161).  
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1.3 METHODOLOGICAL DEVELOPMENT 
All four papers in this thesis rely heavily on multicolor flow cytometry. We utilized this 
technique together with antibodies specific for surface receptors, cytokines and 
transcription factors of interest in NK cell biology. To achieve the staining 
combinations presented in the papers the following challenges were faced: 
 
In all four stories, many antibodies coupled to different fluorochromes were combined, 
leading to problems with spectral overlap from fluorochromes with similar emission 
when cells were analyzed. However, by careful optimization of filter-combinations on 
the flow cytometer, as well as by identifying the right antibody/fluorochrome 
combinations to avoid overlap of signals from bright antigens, we were able to 
simultaneously analyze up to sixteen fluorescence-parameters (Paper I). 
 
In Paper II, we wanted to measure the killing capacity of fetal NK cells, as a 
confirmation that the degranulation we could measure with CD107a upregulation, 
corresponded to actual killing of target cells. Because of limited possibilities to use the 
(51)Cr-release-assay, which is the gold standard for measuring cytotoxic killing (162), 
we developed a flow cytometry-based assay. Target cells were labeled with a 
fluorescent dye, making them easy to gate on when analyzing the data. After plating a 
given number of target cells (5000-10 000 per well), different number of fetal or adult 
effector cells were added each wells, creating different effector:target (E:T) ratios. 
After four hours of co-incubations, all wells were stained with a Live/Dead 
discriminator, and the frequency of dead target cells could be analyzed and plotted 
relative to the E:T ratio, thus illustrating the NK cell killing efficiency. 
 
Due to the high degree of homology between KIR2DL1 and KIR2DS1, no specific 
antibody exists for KIR2DS1. To circumvent this, we used a combinatorial staining 
strategy previously proven successful (163, 164). We first stained cells with the 
specific anti-KIR2DL1 antibody, thus blocking this epitope, and then titrated and tested 
different conditions, to find one that allowed the promiscuous anti-KIR2DL1/S1 (clone 
EB6) to bind to KIR2DS1. Combining this with antibodies against inhibitory KIRs and 
NKG2A allowed dissection of the phenotype and function on freshly isolated 
KIR2DS1+ NK cells (Paper III). 
 
For detailed information on methods used please refer to the methods sections in the 
individual manuscripts and papers. 
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2 AIMS OF THIS THESIS 
 
!"#$%&'(&NK cells and other ILCs have previously been found to develop early in 
human fetal development. It was however not known how early their development 
starts, and whether this process varies between fetal organs, and with gestational age. 
Little was also known about fetal NK cell development, in particular in relation to 
other ILCs. The main aim of this paper was to investigate the development of ILCs in 
human fetal organs by analyzing the unique transcription factors expressed in 
different ILC types, to investigate ILCs in developing human fetal organs. 
&
!"#$%&''. Mature fetal NK cell differentiation and regulation had not previously been 
investigated. Using models of NK cell differentiation, the aim of this project was to 
determine in what organs and to what degree human fetal NK cells are differentiated. 
We also investigated whether fetal NK cells are functional, and if they are 
differentially regulated as compared to adult NK cells. 
 
P"#$%&'''. NK cell education via inhibitory KIRs has been characterized, but whether 
activating KIRs have an impact on NK cell education had not been investigated at the 
onset of this project. The aim of this study was therefore to investigate whether the 
activating KIR2DS1, together with its ligands HLA-C2, had an impact on NK cell 
education. 
 
P"#$%&'). A role for NK cells in virus infections has since long been established. 
However, studies of the human NK cell immune responses during acute viral 
infections are scarce, much because symptom debut and hospitalization often occur 
after the initial immune response, where NK cells primarily take part. The aim of this 
study was therefore to investigate the earliest phases of NK cell responses in a human 
model of an acute viral infection. To this end we analyzed NK cell responses in 
individuals vaccinated with the live attenuated yellow fever virus 17D. 
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3 RESULTS AND DISCUSSION 
3.1 DEVELOPMENT OF FETAL NK CELLS AND OTHER ILCS  
The human immune system starts to develop in the womb. However, not all its 
components develop simultaneously, and whereas innate cells including NK cells (139-
141), and other ILCs (106), have been found already in the first trimester of gestation, 
T cells only develop later (165). When and where innate fetal immune cells start to 
develop, and how ILC function is regulated remains largely unknown. 
 
Identification of human fetal ILCs 
The role in utero of LTi cells in mice has been established, and these cells are 
important in formation of lymphoid structures including lymph nodes and Peyer´s 
patches (95). Less well understood is what functions fetal NK cells and other ILCs 
have. To be able to address questions pertaining to fetal ILCs, we established 
techniques to distinguish these phenotypically similar cells from each other. Both 
surface markers and intracellular proteins can be used for this, and the unique 
transcription factor expression patterns revealed by studies in transgenic mice, 
prompted us to combine antibodies targeting surface markers and transcription factors 
associated with ILC phenotype and function, and to analyze fetal cells using multicolor 
flow cytometry. Our first finding was that cells with group 1-3 ILC phenotypes could 
be identified in fetal gut, lung, bone marrow and liver as early as gestational week six 
(Paper I). Importantly, we did not perform any functional experiments on non-NK 
ILCs, and we thus rely only on their phenotype when we describe them. 
 
NK cells were identified as Eomes+T-bet+/- cells that co-expressed CD56, NKG2A or 
CD16 (Figure 5). RORγt+ cells lacked Eomes and T-bet, and instead expressed the 
highest levels of CD127 and CD117, and thus matched the phenotype of group 3 ILC 
(166). In line with previous studies (52), first trimester fetal RORγt+ cells were mainly 
NCR- (data not shown), and thus resembled LTi cells (52). Interestingly, we also 
identified such cells in the connective tissue isolated from the retroperitoneal cavity, 
which is where the spleen and peritoneal lymph nodes later develop (167).  
 
ILC1s have been described as CD127+T-betlowCD56-CD161+ cells, present in tonsils 
and inflamed gut (115), and as CD127-T-betlowCD56+NKp44+CD103+ in tonsils (116). 
We found cells with similar phenotypes in fetal gut isolated at gestational week 6-10. 
These cells expressed CD161 and low levels of T-bet without Eomes, and could be 
divided into CD127+CD56-, and CD127-CD56+, thus overlapping with the ILC1 
phenotypes previously described in adult tissues. However, Eomes mRNA was 
previously reported to be similar in NK cells and adult CD127-CD56+ ILC1s, (116), 
making these cells less similar to our putative ILC1s, but suspiciously similar to 
conventional NK cells. Whether these phenotypes represent two or more distinct ILC 
subtypes remains to be determined, and our transcription factor staining approach can 
likely aid in this definition. Finally, ILC2s could be identified as GATA-3hiEomes-T-
bet-RORγt- cells. These cells were also highest in CD161 expression, and thus matched 
the previously described fetal ILC2s (112).  
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Figure 5. Representative staining of Lin-CD34-CD45+ fetal gut cells isolated at gestational week 8. 
  
Using these phenotypes we could measure the frequency of each ILC type in different 
tissues in relation to gestational age (Paper I), and found that the frequency varied both 
between ILCs, tissues, and with gestation. NK cells and group 3 ILCs were the 
dominating populations among total ILCs in all tissues from gestational week 6-22. 
Notably, in the organs associated with pronounced lymphoid organ development, i.e. 
the gut and retroperitoneal space, we found more LTi cells than NK cells. Here it is 
noteworthy that the gastrointestinal tract increases in length in a linear fashion early in 
gestation (168), and the number of Peyer’s patches increases from on average 60 before 
gestational week 30, to over 240 at puberty (167), thus likely requiring LTi cells to help 
in the formation of these structures. In contrast, NK cells were most frequent in the 
liver and the lung. ILC2s could not be defined using GATA-3 expression in the second 
trimester samples, since the combinatorial staining for transcription factors was not 
available when those samples were analyzed. However, ILC2s cells make up a large 
part of the Lin-CD34-CD94-RORγt-CD161+ cells, and as such we could estimate the 
frequency of ILC2s. However, the frequency of ILC2s was low in all organs, and did 
not significantly change during the first and second trimester (Figure 5 and Paper I). 
 
Fetal gut contained CD34+CD45RA+CD7+CD117+/- cells, resembling stages 1 and 2 of 
the model for NK cell development suggested by Freud and colleagues (87). Notably, 
the CD34+CD117+ cells found here contained a subset of cells co-expressing RORγt, 
suggesting they are committed to develop into group 3 ILCs, rather than NK cells. 
Moreover, many of these cells expressed CD45RA and CD7, thus still closely 
resembling stage 2 NK cells, and supporting the notion that ILCs have a common 
progenitor. The expression of CD45RA has not been investigated on group 3 ILC 
before, and the expression of CD7 has been debated, as in vitro differentiated RORγt+ 
cells lacked expression of CD7 (105), whereas ex vivo analyzed fetal LTi cells 
expressed CD7 (98). Our analyses of fetal RORγt+ group 3 ILCs suggest they might 
start as CD34+CD45RA+CD7+CD117+CD127dim, and gradually loose CD45RA and 
CD7 as they differentiate they. In line with this hypothesis, the CD34-RORγthiCD117+ 
CD161+CD127+ group 3 ILCs in fetal organs had the lowest expression of CD7 and 
CD45RA (data not shown). 
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Expression of Eomes and T-bet in NK cell development  
The presence of NK cells so early in fetal development is intriguing, and to learn more 
about these cells we characterized fetal NK cell development, function and regulation 
in relation to gestational age, organ and differentiation stage (Paper I and II). 
As introduced above, human NK cells have been found to develop through stages 
defined by expression of combinations of cell surface markers (87). However the 
expression of the transcription factors Eomes and T-bet had not been placed in this 
model. In contrast, these factors have been studied in murine NK cells, and studies 
indicate that T-bet precedes Eomes in mouse NK cell ontogeny (120), since T-bet+ NK 
cells in the liver were present before Eomes+ NK cells in the spleen could be detected. 
Interestingly, although we did not analyze Eomes and T-bet expression in fetal NK 
cells from the spleen, NK cells from all fetal organs contained T-bet+/dim NK cells, only 
among Eomes+ cells, whereas Eomes+T-bet- NK cells also were detected (Paper I). 
Moreover, T-bet was expressed by the vast majority of CD16+ NK cells, which 
represents a later stage of human NK cell development (117, 125). This suggested that 
human fetal NK cells express Eomes prior to T-bet as they develop. NK cells in adult 
peripheral blood expressed both Eomes and T-bet, but whereas CD56bright NK cells 
expressed more Eomes, CD56dimCD16+ NK cells tended to have less Eomes relative to 
their T-bet expression (unpublished observations).  
 
Eomes and T-bet act as regulators of expression of genes associated with NK cell 
function (119). In support of this, further analysis of NK cells using antibodies against 
Eomes, together with functionally related molecules including granzymes and perforin, 
revealed that Eomes+CD94-CD16- NK cells expressed low levels of granzymes and 
perforin, as well as NKG2D. This pointed to an initiation of expression of functional 
molecules prior to acquisition of CD94/NKG2A, but after expression of Eomes. 
Further functional studies of the fetal NK cells showed that only Eomes/T-bet+ NK 
cells responded to cytokine and target cell stimulation (Paper I).  
 
These data thus suggest that Eomes and T-bet expression is initiated at different time-
point in mouse and human NK cell ontogeny. An alternative interpretation of the 
mouse data instead suggests that two different NK cell lineages may exist; one T-
bet+Eomes- liver NK cell, and one later developing T-bet+Eomes+ splenic NK cell 
(169). Notably, mice transgenically modified to lack Eomes or T-bet still had 
functional NK cells, which suggests both NK cells from early mouse ontogeny (Eomes-
T-bet+) and later (Eomes+T-bet+) are functional (120). However, in another mouse 
study, tumor-infiltrating exhausted NK cells were detected, which exhibited an 
EomeslowT-betlow phenotype (170). The exhaustion could be partly rescued by forced 
over expression of Eomes, but not T-bet. Together these functional studies indicate that 
murine NK cell function is influenced by both Eomes and T-bet, but that their functions 
are not entirely overlapping.  
  
It is noteworthy that in spite of the overlap in functions of Eomes and T-bet, ILC1s 
seem to rely solely on T-bet, and not Eomes (Paper I). Since ILC1s and NK cells share 
the capacity to produce IFN-γ, but NK cells alone are cytotoxic, it is tempting to 
speculate that the expression of Eomes is what endows NK cells with this effector 
function.  
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Stage 1-3 fetal NK cell development in relation to other ILCs 
Of the human ILCs, NK cell development has been studied in greatest detail. The 
aforementioned model of NK cell development suggests that CD34+CD45RA+CD117- 
stage 1 and CD34+CD45RA+CD117+ stage 2 NK cell precursors sequentially acquire 
features of mature NK cell as they progress through CD34-CD117+CD161+CD94- stage 
3, to CD94+ stage 4 (117). In light of our findings that Eomes and T-bet are expressed 
seemingly sequentially, we wanted to investigate the pattern of expression of other 
markers associated with NK cell development. Our multicolor flow cytometry 
approach provided means to further decipher fetal NK cell development.  
 
No Eomes or T-bet positive cells were found among CD34+ cells, suggesting these 
transcription factors  are expressed only later in development of NK cells. However, 
among putative fetal stage 3 NK cells (CD34-CD94-CD127-RORγt-CD7+CD161+), a 
CD117-CD122-Eomes-T-bet- population could be found. Based on the presence of cells 
with intermediate expression, they seemed to sequentially acquire CD122, Eomes, and 
CD94, as they differentiated to stage 4. Analysis of such transition states using two-
dimensional FACS-plots is however not optimal, because the analysis risks becoming 
tainted with the subjective views of the operator. To avoid this, we analyzed the 
aforementioned sequential expression of markers with a more objective tool, and used 
SPADE (6) to perform unsupervised cluster analysis of the FACS data. This algorithm 
used twelve-dimensional fluorescence data for each cell to cluster similar events in 
nodes, which are connected to other nodes based on similarity. The size of the nodes is 
proportional to the number of cells with that particular phenotype.  
 
This resulted in a model with three main arms containing CD34+ hematopoietic cells, 
Eomes+ NK cells, and RORγt+ group 3 ILCs, respectively (Figure 6 and Paper I). In 
the beginning of the Eomes+ arm, nodes from CD161+CD122+Eomes- cells, followed 
by CD161+CD122+Eomes+ cells, were clustered. This suggested a sequential 
expression pattern as NK cell precursors approach mature NK cell status, and express 
Eomes and CD94/NKG2A. CD56 expression also clustered together with CD122 in the 
SPADE model, but its expression could also be seen elsewhere in the model, in line 
with its previously demonstrated expression on group 3 ILCs. In contrast, NKG2A+ and 
CD16+ cells clustered only within the Eomes+ cells, and our data indicating CD16 
expression on T-bet+ NK cells was also recapitulated by the SPADE analysis. Together, 
our data supports a model where surface markers and transcription factors are 
expressed in a sequential fashion as NK cells differentiate (Figure 7). Although low in 
frequency in relation to NK cells and group 3 ILCs, SPADE also captured ILC2s, and 
as expected identified them as CD161hiGATA-3hiEomes-T-bet-RORγt- (Paper I). 
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Figure 6. SPADE analysis of fetal gut Lin-CD45+ cells, illustrating clustering of events into three main 
branches based on expression intensities of CD34, Eomes and RORγt. Zoom-boxes illustrate the 
sequential acquisition of NK cell-associated markers. Color indicates relative expression ranging from 
blue to red. 
 
Importantly, although SPADE was a useful tool to interpret our high-dimensional 
cytometry data, our model of NK cell differentiation does not prove the existence of 
any of the suggested intermediate stages. This and other models do however serve as 
useful guides when devising FACS-sorting strategies for future experiments, where 
putative ILC precursors can be sorted and analyzed for differentiation capabilities. A 
first step in such an undertaking is to identify surrogate surface markers for the 
transcription factors, which will allow sorting of living cells. 
 
 
Figure 7. Extended model of human NK cell development and differentiation based on our studies of 
human fetal NK cells. 
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3.2 FETAL NK CELL DIFFERENTIATION AND FUNCTIONAL 
REGULATION 
Following the identification of mature NK cells in the fetus, we asked whether they are 
functional, and whether similar to T cells (171), fetal NK cells exhibit unique features 
as compared to their adult counterparts. To this end we analyzed the phenotype and 
function of mature NK cells in second trimester fetal tissues, as described in Paper II. 
We studied the later stages in fetal NK cell development, namely the CD94/NKG2A 
and CD16 expressing stage 4 to stage 6. NK cells have previously been described in 
fetal liver and spleen isolated at this time in fetal development, but no study had 
applied the current model of mature NK cell differentiation to fetal cells.  
 
Identification of second trimester fetal NK cells 
We used conventional surface markers, and the Boolean algorithm “CD56 or NKG2A 
or CD16”, to identify NK cells among CD7+CD3-CD14-CD19-CD34- cells. As we 
have seen in the previous paragraphs, CD56 can be expressed on non-NK ILCs, and 
to control for this we verified that CD56+NKG2A-CD16- non-NK cell ILCs did not 
make a large contribution to our analysis. In fact, this population reached maximum 
5%, and only in mesenteric lymph nodes (mLNs), and the vast majority of these cells 
co-expressed RORγt.  
 
We started by observing that fetal NK cells were present in multiple fetal organs, 
including the liver, lung, spleen, bone marrow, thymus, skin and mLN (Paper II and 
unpublished observation). The frequency of NK cells within each organ varied 
greatly, and the liver and lung contained the highest frequencies of NK cells. Next we 
analyzed the expression of NKG2A, CD16 and KIR, to obtain information on the 
differentiation status of fetal NK cells. More than 90% of fetal NK cells expressed 
NKG2A, which is similar to cord blood (172). Many fetal NK cells also expressed 
CD16+ (30-80%), indicating differentiation to stage 5, however this frequency was 
not as high as in cord blood (>80-90%) (173). Moreover, the distribution of NK cells 
in the three different subsets defined by NKG2A and/or CD16 expression differed 
between organs, with more differentiated cells found in peripheral organs such as the 
lungs, and more immature NK cells residing in organs associated with fetal 
hematopoiesis, including mLN and liver (Figure 4 and 8). Together with our data in 
Paper I, this suggests possible in situ differentiation of NK cells, possibly attributed 
to local cytokine-milieu, promoting NK cell development in organs such as the liver 
and lungs, whereas group 3 ILCs are promoted in the gut.  
 
Differences between organs was also observed with regards to KIR expression, and 
bulk KIR expression was found to range from 10% in fetal liver and mLN, up to 35% 
in the fetal lung. These distributions of KIR+ NK cells fit with data from adults, 
where more KIR+ NK cells are found in peripheral non-lymphoid compartments 
organs (e.g. the lungs) compared to lymph nodes, tonsils, bone marrow, and also cord 
blood (unpublished observation). 
 
Fetal NK cell differentiation 
NK cell differentiation is coupled to acquisition of CD16, KIR and CD57, but loss of 
NKG2A (136). Analysis of the co-expression of NKG2A, CD16 and KIR on fetal 
cells revealed that NKG2A+CD16-, NKG2A+CD16+, and NKG2A-CD16+ cells 
contained increasing frequencies of KIR+ NK cells, respectively, thus indicating that 
the model developed for adult NK cell differentiation is also valid for fetal NK cells 
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(Figure 8). Moreover, the number of KIRs co-expressed on each NK cell also 
increased in the manner previously observed by us on adult NK cells (131). 
Surprisingly, fetal lung NK cells, which expressed the most KIRs, had more NK cells 
expressing multiple KIRs, than adult peripheral blood NK cells analyzed in the same 
manner (analyzing only CD57- cells).  
 
CD57 is expressed primarily by highly differentiated NK cells, and has been found to 
be very low on cord blood NK cells (131, 173). In line with this, only few CD57+ 
stage 6 fetal NK cells were found in fetal tissues. However, second trimester fetal 
lung did contain a small population of CD57+ NK cells, which expressed CD16 
(Paper I) and KIRs (unpublished observation), indicating that CD57 marks highly 
differentiated NK cells also in the fetus. Together this suggests that the fetal NK cell 
pool is largely naïve in terms of NKG2A and CD57 expression, which resembles 
immature NK cells in adult peripheral blood. However, the expression of KIR more 
resembles differentiated NK cells, and although relatively few KIR+NKG2A+CD57- 
NK cells are found in adult peripheral blood, NK cells with this phenotype has been 
found in e.g. the uterus, indicating that different KIR+ NK cell phenotypes exist at 
different stages of our life, and in different tissues. 
 
 
     
 
Figure 8. Distribution of NKG2A and/or CD16 expressing NK cells (left), and number of KIRs co-
expressed on subsets of NK cells (right). Second trimester fetal organs. mLN: mesenteric lymh node, 
BM: Mone marrow, UCB: Umbilical cord blood, aPBMC: adult PBMC. 
 
Possible consequences of KIR expression on fetal NK cells 
It is noteworthy that human fetal NK cells display a differentiated phenotype, 
including expression of cytotoxic molecules, and receptors known to endow NK cells 
with functionality, including the education via NKG2A and KIR. In mice, mature NK 
cells are few in the fetus (137), and Ly49+ NK cells are virtually absent (138) 
(whereas NKG2A expression on fetal mouse NK cells has not been reported). This 
has been interpreted as evidence of adaptations to ensure fetal-maternal tolerance 
(138). Indeed, maternal cells can cross over the placenta, together with nutrients, 
antibodies and pathogens (174). Such maternal cells create interesting demands on 
the involved immune cells, and the reverse is seen with fetal cells crossing over to the 
mother (175). Maternal cells in the fetus could be semi-allogeneic, and express HLA 
that fetal NK cells have not seen. If fetal NK cells were regulated similarly to adult 
NK cells, including education via inhibitory receptors with polygenic ligands (i.e. 
KIRs), it is plausible that fetal NK cells may interact with maternal cells, and not be 
inhibited. Such NK cell activity could be harmless, and take place so rarely that it has 
not affected the reproductive success of our species. Alternatively, such activation 
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could have unfavorable consequences and affect the outcome of the pregnancy 
negatively, which might have given rise to adaptations that minimize such effects. 
One way to learn which of these scenarios is closest to the truth was to investigate 
whether fetal NK cells are differentially regulated as compared to adult NK cells. 
 
Functional regulation of fetal NK cells 
Previous studies had shown that fetal NK cells are functional but exhibit lower levels 
of activity than adult NK cells (140). We could corroborate these data regarding NK 
cells both from first (Paper I) and second trimester (Paper II). It had however not 
been investigated how fetal NK cells are regulated via inhibitory receptors. NK cells 
in cord blood express more NKG2A than NK cells in adult blood (172), and 
Schönberg et al. found that cord blood NK cells were educated via both NKG2A and 
inhibitory KIRs (176). To investigate if fetal NK cells exhibit this conventional type 
of NK cell education, we stimulated fetal NK cells with K562 cells. In line with 
previous studies, fetal NK cells degranulated in response to such stimulation, but to a 
lower degree than adult NK cells on a bulk level (Paper II). 
 
Next we investigated whether fetal NK cells are educated. We first analyzed KIR- NK 
cells expressing or lacking NKG2A. This showed that NKG2A does educate fetal NK 
cells, since NKG2A+ NK cells degranulated more than NKG2A- NK cells. Because 
the frequency of NKG2A- NK cells was so low (<5-10%), we analyzed education via 
inhibitory KIR within the NKG2A+ subset, thus measuring the potential added effect 
afforded by KIR-education, on top of the NKG2A-mediated education. To this end, 
DNA was isolated from fetal cells and the presence of KIR-ligands was determined 
by PCR. NK cells expressing self-KIR, non-self KIR, or no KIR (using antibodies for 
KIR2DL1, KIR2DL3 and KIR3DL1) were then compared in terms of response to 
K562. Following this analysis, we obtained the perhaps most fascinating result in this 
thesis: fetal NK cells expressing KIR were hyporesponsive in relation to KIR- NK 
cells, irrespective of presence of KIR-ligands (Figure 9). In fact, similar to the tuning 
process of inhibitory receptors in adult humans and in mice (77), expression of one or 
more KIRs on fetal NK cells was associated with decreased responsiveness, in a 
seemingly dose-dependent manner. Colleagues of ours have described a similar effect 
of KIR expression on CD8 T cells expressing KIR (177), potentially pointing to 
common pathways of KIR-mediated hyporesponsiveness in fetal NK cells and adult T 
cells. In contrast, adult NK cells increased in functional responsiveness when more 
KIRs were expressed (Figure 9).  
 
We next investigated if only natural cytotoxicity was affected by this differential 
regulation, or whether also antibody-dependent cytotoxicity (ADCC) and cytokine 
stimulation of fetal NK cells was affected. To this end we analyzed fetal NK cells 
after co-culture cells with 721.221 cells (a CD20+ B cell line) together with 
Rituximab (an anti-CD20 antibody). Fetal NK cells degranulated and killed target 
cells, but also in this setting KIR+ NK cells responded less than KIR-. Finally, also 
cytokine-primed fetal NK cells expressing KIRs remained lower in response to target 
cell stimulation, corroborating the idea that KIR expression on fetal NK cells is 
associated with a hyporesponsive phenotype, and that this is an intrinsic feature. 
However, cytokine stimulation induced a strong IFN-γ production in all fetal NK cell 
subsets, which together with their capacity to mediate ADCC suggests that fetal NK 
cells might contribute to immune responses in utero. 
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Figure 9. Functional responses of fetal lung NK cell subsets, as compared to adult peripheral blood 
NK cells, following co-culture with K562 target cells. Self-KIR (S), non-self KIR (NS), KIR negative 
NK cells (-). Right panels summarizes the relative changes in response relative to KIR negative NK 
cells. 
 
In relation to the suggested scenarios introduced above, one interpretation of our 
results is that this alternative education of fetal NK cells represents evolutionary 
adaptations to pressures from the presence of maternal cells crossing the placenta, 
leading to a demand for a tolerance mechanism. The same pressure would not have 
acted on education via NKG2A, because its ligand, HLA-E, is not polymorphic and 
will be the same on both maternal and fetal cells. The education via NKG2A could 
instead be beneficial, since it would allow fetal NK cells to sense infected or 
transformed cells that have lost HLA-E, irrespective of origin, while remaining 
tolerant to maternal cells. Indeed, perhaps evolutionary pressure has driven fetal NK 
cells to almost uniformly express NKG2A. The propensity to express many KIRs on 
the same fetal NK cell might also be the result of selective pressures to ensure 
tolerance; expression of many KIRs is likely to ensure tolerance via one or more 
KIR/KIR-ligand pairs, if a fetal NK cells interacts with a maternal cells with semi-
allogeneic HLA class I. However, if fetal KIR expression is only associated with 
problems, it is reasonable to ask why they are expressed at all in utero, and why their 
expression is not initiated until closer to birth, like their counterparts in mice. 
 
Effects of TGF-β on fetal NK cell function 
Fetal lymph nodes have been found to contain elevated levels of TGF-β transcripts 
(178), and this cytokine is known to be highly expressed in the placenta, likely 
leading to relatively high levels also in the fetus (179). Moreover, murine NK cell 
ontogeny is influenced by TGF-β, and NK cells lacking TGF-β signaling had more 
mature NK cells at birth than controls, indicating a role in mouse NK cell maturation 
(138). In adult humans, NK cell function is inhibited by TGF-β (180, 181). Based on 
this data we hypothesized that increased susceptibility to TGF-β could explain the 
hyporesponsiveness exhibited by KIR+ fetal NK cells. We were however unable to 
test this using fetal organ cells, due to logistic reasons, and instead we used cord 
blood isolated routinely from in utero blood transfusions of fetuses in gestational 
week 18-31. These blood transfusions are performed due to anti-RhD immune 
responses from the mother to fetal erythrocytes, and the isolated cells do therefore not 
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represent healthy cord blood. Nevertheless, KIR+ fetal blood NK cells were 
confirmed to be hyporesponsive in relation to KIR- NK cells, whereas NKG2A+ NK 
cells were educated, indicating that the fetal blood NK cells exhibited the same 
features as fetal organ NK cells.  
 
We co-cultured fetal and adult peripheral blood NK cells with either TGF-β or a 
TGF-β receptor signaling inhibitor for 48 hours, and subsequently added 721.221 
cells coated with Rituximab, thus exposing the NK cells to an ADCC situation. Fetal 
blood NK cells were significantly inhibited by TGF-β stimulation, whereas the 
inhibitor had the opposite effect, indicating TGF-β signaling is active in the cells. 
However, both KIR- and KIR+ NK cells showed the same response to TGF-β or the 
signaling inhibitor, indicating the KIR-associated hyporesponsiveness is not a TGF-β 
mediated feature. Nevertheless, it was notable that fetal NK cells were affected by 
TGF-β in vivo, thus potentially functioning as an additional tolerance inducing 
mechanism, together with the NKG2A expression on fetal NK cells, and their 
differential regulation via KIR. 
 
Interpretation of fetal ILC data 
As discussed above and in Paper I, it is possible that the frequency of LTi cells is 
correlated to the formation of lymphoid structures including Peyer’s patches in the gut, 
as well as in the peritoneal cavity where lymph nodes and the spleen is formed. While 
this notion is intuitively pleasing, in contrast, the reason for the early presence of NK 
cells and ILC2s, and possibly ILC1s, at this stage in fetal development is still not 
known. Whereas mice lack mature NK cells in utero until late in gestation (137), 
humans develop them very early in pregnancy, and they are also differentiated and 
functional, thus pointing to different demands on the human ILC components.  
 
Of the many differences between the mice and humans, one that might be relevant is 
the fact that mice have many pups, thus lessening the demand for each pup to survive, 
from an evolutionary point of view. Our species instead invests all our energy into 
(usually) only one offspring. Moreover, whereas mouse gestation is only three weeks, 
the longer time in the womb needed for human fetal development increases the risk of 
in utero infections. It is thus possible, as was suggested above, that human fetal innate 
cells develop early to aid in defense against in utero infections, and to maximize the 
likelihood of survival of our offspring.  
 
As an example, CD16+ fetal NK cells could potentially use maternal antibodies that 
cross the placenta, to find and eliminate virus-infected cells. Moreover, other innate cell 
subsets, including macrophages, DCs and eosinophils have been also been identified in 
the developing fetus (182), and as we have illustrated, fetal NK cells can be a source of 
IFN-γ in response to stimulation via IL-12 and IL-18 produced by these other innate 
cells. The IFN-γ can possibly activate fetal macrophages to kill engulfed pathogens, 
thus functioning just as in adult immune responses to pathogens. Moreover, NK cell 
immune surveillance via NKG2A-mediated licensing might be used to detect aberrant 
proliferating cells that likely arise during the many cell divisions that per definition take 
place during organogenesis and fetal development. ILC2s are also present early in 
human fetal development and have been demonstrated to produce IL-5 and IL-13 ex 
vivo (112), and might thus also take part in immune responses in utero. 
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Starting their developmental program early will also ensure that NK cells, ILC2s and 
other innate cells will be in place at birth, where the transition from life in the womb to 
the outside world involves the risk of pathogens invading the newborn, in particular 
through the lungs and gastrointestinal tract. Here an important aspect is also the 
establishment of the commensal flora of the gut and lungs, which likely involve innate 
cells in many ways yet to be discovered. Importantly, none of these suggested roles of 
fetal innate cells are mutually exclusive, but might together have been beneficial to the 
successful development and survival of fetuses, as our species has evolved. As 
discussed previously, this seems to have been worth the risk of potential fetal-maternal 
immune activation, which however appears to have resulted in adaptations involving 
differential regulation of NK cells via KIR, and inhibition via TGF-β. 
 
How fetal NK cells can be different than adult NK cells in terms of their regulation can 
be interpreted in the context of a model suggesting that “layers” of immune cells 
develop at different time-points in our ontogeny (171, 183, 184). The features of these 
layers have possibly been shaped by the unique demands put on fetal immune cells, in 
contrast to adult immune cells, such as the need for fetal-maternal tolerance. Members 
of our group have shown that fetal T cell progenitors had a much higher propensity to 
become regulatory T cells, as compared to phenotypically similar progenitor cells 
isolated from adult humans (185). It is tempting to speculate, as we do in Paper II, that 
also human NK cell (and possibly non-NK ILC) ontogeny is layered. A prediction from 
this hypothesis would then be that fetal NK cell progenitors, in spite of exhibiting 
similar phenotypes as adult progenitors (e.g. CD34, CD45RA, and CD117 expression), 
would give rise to NK cells with unique features, including those described by us in 
second trimester fetal tissues. Future studies are warranted to address this intriguing 
prospect. 
 
3.3 EDUCATION OF NK CELLS VIA ACTIVATING KIR 
As introduced above, NK cells are educated by the presence of their cognate KIR-
ligands, and are activated when inhibitory signals are missing. The inhibitory receptors 
maintaining NK cell inhibition at steady state include NKG2A and inhibitory KIR, 
whose ligands are HLA class I molecules expressed on healthy normal cells. In 
addition to the inhibitory KIR, NK cells can express activating KIR, including 
KIR2DS1. The ligand for KIR2DS1 is HLA-C2, which is the only known ubiquitously 
expressed ligand for an activating KIR. Given the stochastic nature of KIR expression 
on NK cells, it is possible that NK cells express only KIR2DS1, without co-expression 
of inhibitory receptors. However, in an individual homozygote for HLA-C2/C2, such 
an NKG2A-KIR2DS1sp (single-positive) NK cell could potentially be autoreactive.  
 
One possibility to avoid such a situation would be to negatively select against NK cells 
with this phenotype, a scenario that would be implied by the absence of KIR2DS1sp 
NK cells in the NK cell pool of HLA-C2/C2 individuals. Alternatively, such NK cells 
might be differentially educated in vivo, and be hyporesponsive in individuals 
expressing the cognate ligand. Interestingly, prior to our study (Paper III), in vitro 
expansion experiments where KIR2DS1+ NK cell clones were generated showed that 
KIR2DS1 is functional and activates the NK cell via HLA-C2 (164). This confirmed 
the potential risk posed by KIR2DS1+ NK cells present in HLA-C2+ donors. However, 
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whether KIR2DS1sp NK cells existed in vivo, or whether they were selected against 
due to the risk of autoreactivity, remained unknown. To investigate the existence and 
regulation of KIR2DS1sp NK cells in vivo, in relation to NK cells positive for other 
KIRs, we first had to overcome the problem posed by the close homology of KIR2DS1 
and KIR2DL1. Because of their similarity, no specific antibody for KIR2DS1 exists, 
but other studies had shown that combinations of anti-KIR antibodies with different 
specificities allowed detection of KIRsp NK cells (163).  
 
To this end, by first staining cells with an anti-KIR2DL1 antibody we found that this 
partially blocked KIR2DL1 binding sites. We then shortly after added an anti-
KIR2DL1/S1 antibody, which then was able to bind only to KIR2DS1 binding sites 
(Figure 10). By combining this strategy with antibodies against inhibitory KIRs and 
NKG2A, this allowed us to show that KIR2DS1sp NK cells are present in vivo. 
Moreover, we could use this staining technique to study the impact of this receptor on 
NK cell regulation and function (Paper III).  
 
 
Figure 10. Combinatorial staining of NK cells with anti-KIR2DL1 and anti-KIR2DL1/S1 antibodies 
permits detection of KIR2DL1 and KIR2DS1 co-expressing subsets of NK cells. 
 
Influence of HLA-C2 on KIR2DS1 expression and KIR2DS1+ NK cell function 
Previous work had shown that KIR repertoires are formed independently of the 
presence of KIR-ligands (35, 176). To investigate if this applied also to KIR2DS1, we 
analyzed the frequency of NK cells expressing KIR2DS1 in KIR2DS1 positive, HLA-
C1/C1, C1/C2 and C2/C2 donors. This revealed that the frequency of KIR2DS1+ NK 
cells did not significantly differ between donors with different HLA-C status, and 
suggested that KIR2DS1 expression is not affected by the presence of its ligand 
HLA-C2.  
 
Next we co-cultured cytokine-primed NK cells with K562 cells, and compared the 
responses in individuals where the ligand for KIR2DS1 was present (HLA-C2/C2) or 
absent (HLA-C1/C1). Notably, KIR2DS1sp NK cells in HLA-C2/C2 individuals 
were hyporesponsive compared to NKG2A-KIR- NK cells. In contrast, no such effect 
was seen in HLA-C1/C1 donors. Furthermore, the hyporesponsiveness of 
KIR2DS1sp NK cells in HLA-C2/C2 individuals was also evident after stimulation 
via CD16, even without cytokine priming. Together this indicated that 
KIR2DS1/HLA-C2 conferred hyporesponsiveness, and that KIR2DS1sp NK cells are 
differentially regulated compared to conventional education via inhibitory KIRs and 
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NKG2A, presumably to ensure tolerance in HLA-C2/C2 individuals. Interestingly, 
HLA-C1/C2 heterozygote donors displayed an intermediate hyporesponsiveness, 
suggesting a dose-dependent effect of the KIR2DS1-related education. The concept 
of disarming of NK cells following chronic stimulation via an activating receptor 
offers one interpretation of these data (73). On that note, mouse studies have 
demonstrated that continuous engagement of the activating receptor Ly49H results in 
dampened responsiveness of Ly49H expressing NK cells (186, 187). In line with our 
data, this process was found to be dependent on interaction between receptor and 
ligand in vivo (188).  
 
Effects of KIR2DS1 on NK cell education 
Experiments with in vitro generated NK cell clones expressing KIR2DS1 suggested 
that these cells are hyporesponsive when interacting with HLA-C2+ targets, if the 
donor is HLA-C2/C2 (164, 189). We had identified KIR2DS1sp NK cells in vivo, and 
we therefore next investigated whether these cells indeed were tolerant to target cells 
expressing HLA-C2. To test this, we co-cultured freshly isolated NK cells from 
HLA-C2/C2 donors with HLA-C2+ tumor target cells, and found that KIR2DS1sp 
NK cells were hyporesponsive, which suggests they are tolerant to self (HLA-C2) in 
vivo. Interestingly, KIR2DS1sp NK cells from HLA-C1/C1 donors were not 
hyporesponsive, which may have beneficial effects in some transplant settings, which 
is discussed more below. 
 
The array of HLA class I-binding inhibitory receptors including KIR and NKG2A, 
and activating receptors together transmit both inhibitory and activating signals upon 
an interaction with target cells, and the integrated signals determines the level of 
response following stimulation. This process has been referred to as tuning of the NK 
cell response, analogous to a rheostat (68). We next investigated whether KIR2DS1 
affected the level of responses from NK cells co-expressing KIR2DS1 with inhibitory 
receptors. Indeed, analysis of the effect from KIR2DS1 on subsets expressing other 
KIRs and NKG2A indicated that KIR2DS1 tunes down the responsiveness of NK 
cells educated via KIR3DL1, KIR2DL3 and NKG2A, but only if HLA-C2 is present. 
In contrast, co-expression with KIR2DL1, which also binds to HLA-C2, did not lead 
to a significant reduction in responsiveness. This suggests that KIR2DL1-signaling 
has a dominant effect over KIR2DS1-signaling when these two receptors are co-
expressed. 
 
Up to this point our data indicated that KIR2DS1 conferred hyporesponsiveness, and 
we wondered whether the receptor is at all functional on NK cells from HLA-C2+ 
individuals. To this end, we stimulated NK cells with anti-KIR2DL1/S1 antibody-
coated P815 cell, thus directly stimulating KIR2DS1. Interestingly, this resulted in 
robust degranulation from KIR2DS1+KIR2DL1- NK cells, irrespective of HLA-C 
status. Moreover, stimulation with IL-12/15 resulted in IFN-γ production in KIR- and 
KIR2DS1sp NK cells alike. Together, these functional experiments suggested that 
while being differentially educated to ensure tolerance, KIR2DS1 is a functional 
receptor in vivo, and KIR2DS1sp NK cells can be activated by cytokines to produce 
proinflammatory cytokines including IFN-γ. It also remains possible that hitherto 
unidentified ligands for KIR2DS1 exist in vivo. These could for instance be virus 
peptides presented by HLA-C2, which could make HLA-C2 into a strong ligand for 
KIR2DS1. Alternatively, tumor-induced ligands for KIR2DS1 might exist. In both 
cases, KIR2DS1sp NK cells in both HLA-C1 and HLA-C2 individuals might then be 
advantageous in vivo. 
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Implications of KIR2DS1/HLA-C2-mediated education 
The use of NK cells and information about KIR is increasing in the field of bone 
marrow transplantation of cancer patients (190). Here, transplantation with CD34+ 
cells from KIR2DS1+ individuals is correlated with a lower risk of relapse in patients 
with leukemia, as long as the donor is not HLA-C2+ (191). This data fits with our data 
discussed above; KIR2DS1 educates NK cells to be tolerant and hyporesponsive in 
the presence of its ligand HLA-C2. Furthermore, it suggests that it might be advisable 
to avoid donors positive for both KIR2DS1 and HLA-C2, where anti-tumor effects are 
the goal, since these NK cells will be hyporesponsive. Future studies using the 
staining combination to analyze KIR2DS1+ NK cells could prove to be useful when 
matching donors and recipients. Notably, following transplantation of CD34+ cells, 
the KIR repertoire of the donor has been found to largely be recapitulated by the 
recipient (123). Choosing donors with larger KIR2DS1+KIR2DL1- populations of NK 
cells in HLA-C2- donors might thus be beneficial if transplanted into an HLA-C2+ 
recipient. 
 
Research focusing on tissue-resident NK cells and other ILCs is coming of age (106). 
In particular, the aforementioned uterine NK cells have been implicated in pregnancy, 
in the process of implantation of the embryo (57). Here, fetal trophoblasts (expressing 
HLA-C, E and G, but not HLA-A and B) invade into the uterine wall (which is also 
called the decidua) and widen maternal spiral arteries, thus establishing and ensuring 
sufficient supply of nutrients to the growing placenta and fetus. Decidual NK cells are 
suggested to interact with the trophoblasts, and to take part in regulating the depth of 
trophoblasts invasion. Too little invasion can lead to low supply of nutrients to the 
fetus, which in turn is associated with reproductive disorders including recurrent 
abortions and preeclampsia. Deeper invasion by the trophoblasts is beneficial to a 
certain degree, but can also have negative consequences (192). 
 
Decidual NK cells are CD56superbrightCD9+NKG2A+ and predominantly express 
KIR2DL1/S1 and KIR2DL2/3 (193), which gives them a phenotype distinct from 
conventional KIR+ CD56dim NK cells in the peripheral blood. Using the staining 
strategy that combined anti-KIR2DL1 and anti-KIR2DL1/S1 antibodies, it was 
recently revealed that decidual KIR2DL1sp, KIR2DS1sp and KIR2DL1+KIR2DS1+ 
NK cell subsets are all functional, but that activation of them leads to different genes 
being transcribed (194). In particular, stimulation of KIR2DS1sp cells (but not to the 
same extent KIR2DL1+KIR2DS1+ cells) with an HLA-C2+ target cell resulted in GM-
CSF gene transcription, and KIR2DS1 cross-linking translated into GM-CSF 
secretion. This GM-CSF could in turn be used to attract trophoblasts in a transwell 
system, thus implying that activation of decidual NK cells can affect the chemotaxis 
of fetal trophoblasts. Importantly, the results suggest that such activation will depend 
on the KIR-ligand status of the fetus, and of the KIR repertoire of the mother, since 
this will determine whether KIR2DS1 and HLA-C2 will be present. Notably, studies 
from the same group had previously linked combinations of KIR/KIR-ligand genes 
with risk of recurrent abortion and preeclampsia, and maternal KIR2DS1 had been 
found to be protective in the presence of fetal HLA-C2 (38). Together, these genetic 
and functional studies indicate an important role for decidual NK cells regulated via 
KIR/KIR-ligand interactions. 
 
No other ubiquitously expressed ligand for activating KIR has been identified, and 
the role played by KIR2DS1 in reproduction is the strongest data to date implying a 
role of KIRs in healthy human physiology. Given the central role pregnancy and fetal 
development plays for the survival and evolution of a species, it has been speculated 
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that KIR2DS1 evolved for this purpose. Only the great apes (except orangutans) have 
KIR2DS1, and one theory suggests that KIR2DS1 might have evolved to counteract 
the inhibitory role that KIR2DL1 plays in decidual NK cell interaction with 
trophoblasts (23). Supporting this notion, KIR2DL1 inhibited GM-CSF production 
when interacting with HLA-C2, whereas co-expression of KIR2DS1 overcame this 
inhibition, and resulted in production of GM-CSF (194). A potential consequence of 
this, suggested by Parham and Moffett, is that the evolution of KIR2DS1, and 
KIR2DS1+ decidual NK cells in our ancestors, might have allowed deeper invasion of 
trophoblasts, leading more nutrients to pass over to the developing fetus. This in turn 
might have contributed to the evolution of the large brains found in modern humans 
(195). 
 
3.4 NK CELL RESPONSES IN A MODEL OF ACUTE VIRAL INFECTION 
To develop vaccines against pathogens and different cancers represent a holy grail for 
immunologists. One important component of this work is to identify correlates of 
immune-mediated protection. Only with knowledge of such correlates can we design 
and evaluate vaccines in an effective manner. Adaptive immunity in the form of B and 
T cell memory against a pathogen are considered the main factors of a vaccine 
response. However, it is well established that components of the innate immune system, 
including NK cells, play important parts in shaping the adaptive immune response (64-
66). Moreover, adaptive “memory” features of NK cells have recently been shown to 
exist (196). Together, this makes it interesting to characterize NK cell responses to 
virus infections (Paper IV). 
 
Although NK cells are often mentioned as important players in control of virus 
infections, few human studies have followed the early immune response of NK cells to 
a virus infection. Patients suffering from a virus infection commonly do not seek help 
early enough for NK cell responses to be detected, and thus patient cohorts are hard to 
establish. Moreover, for obvious reasons humans, unlike mice, cannot be infected with 
a virus in a controlled manner. However, certain existing vaccines consist of live 
attenuated viruses, and by collecting blood from individuals receiving a vaccine, it is 
possible to follow the early immune response, including the contribution by NK cells, 
and also to potentially identify correlates to protective immunity.  
 
Yellow fever virus vaccine induces NK cell activation and proliferation 
In paper IV we analyzed the NK cells of 21 individuals vaccinated against yellow 
fever virus 17D (YF17D). Using multi-color flow cytometry we analyzed NK cells at 
different stages of differentiation (NKG2A and CD57 co-expression), as well as their 
education status (NKG2A and KIRs). We analyzed PBMC isolated on day 0, 3, 6, 10, 
15, and 90 from vaccinated individuals. 
 
It is well established that hematopoietic cells upregulate CD69 when activated (197). 
Although a clear physiological role for CD69 is still being investigated, it is commonly 
used as a marker of activated lymphocytes, including NK cells. To this end we 
analyzed its expression on NK cell subsets in relation to YF17D vaccination. This 
revealed an increase in CD69+ NK cells on day six post vaccination, and in particular in 
the NKG2A+CD57- subset (Paper IV). At steady stage, this subset is relatively 
immature, and has a high proliferative capacity, but relatively low KIR expression 
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(136), indicating YF17D vaccination leads to activation of preferentially immature NK 
cells.  
 
In addition to activation, we also analyzed the proliferation of NK cells in response to 
vaccination, by analyzing the expression of nuclear protein Ki-67. This protein is 
exclusively expressed in cells undergoing replication (198). Here we found an increase 
in Ki67+ NK cells at day ten (Figure 11). Also this response was seen predominantly in 
immature CD56dimCD57- NK cells. In another study using a similar vaccination model, 
CD56dimCD62L+ cells (largely overlapping with the NKG2A+CD57- NK cells (131, 
134)) predominantly upregulated Ki67 at day seven post vaccination (134). 
Interestingly, the Ki67+ NK cells did not overlap with the CD69+ NK cells, indicating 
that at a given time-point post vaccination, different subsets of preferentially immature 
CD56dim NK cells are activated (CD69+), whereas others are proliferating (Ki67+). 
 
 
Figure 11. Expression of CD69 and Ki67 on CD56bright and CD56dim NK cells following vaccination 
against Yellow Fever. 
 
Possible events leading to YF17D induced NK cell responses 
Wild type yellow fever is known to infect DCs in lymph nodes, prior to its spread to 
Kupffer cells in the liver (199). Interestingly, a systems biology approach, investigating 
the change in expression of hundreds of genes in PBMC following vaccination with 
17D, revealed increases in e.g. CD86 (a marker of DC activation) and pro-
inflammatory IL-1β on day seven post-vaccination (200). Subsequent in vitro 
experiments with monocyte-derived DC co-incubated with 17D virus showed that IL-
1β protein was produced within 24 hours. This suggests that shortly after YF17D 
vaccination, DCs are activated and IL-1β is produced.  
 
As previously discussed, NK cells are primed by IL-12 in combination with IL-15 or 
IL-18. Interestingly, IL-1β belongs to the same family of cytokines as IL-18, and 
studies have indicated that (predominantly) CD56bright NK cells are susceptible to 
activation via IL-1β in combination with IL-12 (201). IL-12 could not be detected by 
us (data not shown) or by others performing similar studies with YF17D (202) in the 
plasma of vaccinated individuals. Nevertheless, the elevated levels of type I/III 
interferons and viral load found in vaccinated individuals day six post vaccination, 
suggests activation of DCs. This in turn makes it possible that IL-12 was produced, but 
perhaps only in physiologically relevant (and detectable) concentrations locally, i.e. in 
the lymph node where infection takes place.  
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Together this suggests that YF17D virus infects and/or activates DC in the draining 
lymph nodes of vaccinated individuals, leading to IL-1β, type I/III IFN and IL-12 
production. What effect this DC activation has on NK cells is not clear, but from our 
data we know that NK cells are both activated (CD69), and stimulated to proliferate 
(Ki67). However, different NK cell subsets expressed CD69 and Ki67, suggesting they 
have been affected in different manners, perhaps because they exhibit different 
phenotypes, or that the same NK cells are first activated (CD69), and then proliferate 
four days later (Ki67). Lymph node NK cells are predominantly immature CD56bright 
and have been suggested to differentiate into CD56dim NK cells (87).  
 
One possible scenario is thus that CD56bright NK cells might be activated by DC-
derived factors, and upregulate CD69, and initiate differentiation. Possibly, these NK 
cells then egress the lymph node, and can be detected on day six in the peripheral 
blood. The same cells might then also proliferate, and appear in peripheral blood as 
Ki67+ immature CD56dim NK cells on day 10 (or on day seven as reported by Juelke et 
al. (134). CD69 upregulation is described as transient (197), but to the best of my 
knowledge, it is not known whether activation of NK cells and upregulation of CD69 is 
followed by proliferation. Alternatively, the CD69+ and Ki67+ NK cell populations 
represent distinct subsets of NK cells, that for unknown reasons are affected differently 
by the vaccination. 
 
In vivo priming of NK cells following vaccination 
Stimulation of NK cells with IFN-α, or IL-12 in combination with IL-15, IL-18, IL-1β, 
or IL-21 activates NK cells (60, 201). Subsequent challenge of the NK cells with target 
cells leads to increased degranulation and killing, as well as production of e.g. IFN-γ 
and TNF-α, both with and without target cells present (61). 
 
In the vaccinated individuals we found that NK cell responses to IL-12 alone; IL-12 
and IL-18; and K562 target cells, peaked on day six post vaccination, thus coinciding 
with activation as indicated by CD69 expression. This increase in response is indicative 
of an in vivo priming of NK cells sampled at this day, leading to a higher response 
when challenged ex vivo. Relating this data to the hypothesis of NK cell activation 
discussed in the previous paragraph, it is interesting to note that IL-12 alone induced a 
strong response ex vivo after vaccination. A potential explanation for this is that NK 
cells sampled at day six post vaccination have been primed in vivo by DCs, which in 
turn had been activated by the virus during the first day post vaccination. This might 
have lowered the threshold for subsequent NK cell activation. Priming of NK cells by 
cytokine exposure has also been described to be long lasting and has been called 
cytokine-induced memory (196). However, although we saw a clear priming effect on 
day six, this effect was transient, and evidence of cytokine-induced NK cell memory 
was not found. The priming did however translate into both increased IFN-γ production 
and degranulation against K562 cells (Paper IV).  
 
NK cell education and KIR repertoires in vaccinated individuals 
NK cell responses to CMV virus leads to an expansion of self-KIR+ cells, as well as an 
increase in differentiated NK cells as measured by frequency of CD57+ NK cells (36, 
155). Flaviviruses are known to increase the MHC class I expression in infected cells, 
thus potentially inhibiting NK cell activation by increasing inhibition via KIRs and 
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NKG2A (203). To this end, it was possible that the virus differentially affected NK 
cells expressing different KIR repertoires. We therefore used multicolor flow cytometry 
panels with antibodies targeting all educating KIRs, including activating KIR2DS1. 
However, we found no evidence of effects on the KIR repertoire following YF17D 
vaccination; the KIR receptor profile of NK cells isolated from vaccinated individuals 
was instead stable from day 0 to day 90, similar to the stability of KIR repertoires 
described previously by us in healthy individuals (36). Moreover, we could find no 
vaccine-induced difference in responsiveness when stimulating the cells ex vivo, 
indicating that NK cell priming in vivo affected educated and non-educated NK cell 
subsets equally.  
 
Considerations for future studies 
Several possible NK cell receptor ligands have been identified on infected cells. NKp44 
is induced on activated NK cells and it has been suggested to interact with cells 
infected with influenza, HIV, HCV, and mycobacteria (204). It has also been found to 
interact with the envelope glycoprotein (E-protein) of members of the flavivirus family 
(205), suggesting activated NK cells may be able to kill virus-infected cells. During the 
course of natural yellow fever infection, liver cells are eventually infected, and in 
studies of paraffin-imbedded liver sections from yellow fever victims, increased 
numbers of NK cells were found close to the liver lesions (206). However, NK cells 
were here identified as CD57+ cells, and a more rigorous characterization is warranted. 
Nevertheless, together this suggests that activated NK cells expressing NKp44, may be 
important players in elimination of virus-infected cells in the liver of later stages of 
yellow fever disease. Whether this interaction can take place in other sites of the body, 
such as the lymph node, where the primary immune response to flaviviruses takes place 
(203), remains to be investigated. Notably, also ILC3s express NKp44, and ligation led 
to production of TNF-α (107). Moreover, ILC3s are present in the human liver  
(J. Mjösberg personal communication) and it thus possible that they take part in yellow 
fever immune responses. 
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4 CONCLUDING REMARKS 
The field of NK cell research has for long been trailing that of other lymphocytes 
including B and T cells. However in recent years, many discoveries of NK cell 
development, differentiation and regulation have been made, and NK cells have been 
grouped as a member of the innate lymphoid cells (ILCs).  
  
Key findings in our investigations are: 
 
• Human fetal NK cells, ILC2s and group 3 ILCs could be detected using 
transcription factor analysis by flow cytometry, and were found in multiple fetal 
organs as early as gestational week six. 
 
• Fetal stage 3 NK cells did not express CD127, CD117 or RORγt, and were thus 
distinct from CD127+GATA-3hi ILC2s, and RORγt+ group 3 ILCs. Cluster 
analysis of FACS-data suggest a model where stage 3 NK cells sequentially 
acquire CD161, CD56, CD122, Eomes, CD94/NKG2A, T-bet and CD16, as 
they differentiate to mature NK cells. 
 
• Mature fetal NK cells were hyporesponsive in natural cytotoxicity settings, 
compared to NK cells from adults. CD94/NKG2A educated fetal NK cells, but 
KIR+ NK cells were hyporesponsive to target cells, indicating a fundamental 
difference between NK cell education in utero as compared to after birth. Fetal 
NK cells were also highly sensitive to TGF-β mediated inhibition. Notably, all 
fetal NK cells subsets produced high amounts of IFN-γ in response to cytokine 
stimulation, and CD16+ fetal NK cells killed antibody-coated target cells. 
Together these findings suggest a unique regulation of fetal NK cells that 
potentially allows them to take part in immune responses in utero, while still 
remaining tolerant to maternal cells crossing the placenta. 
 
• Adult NK cells expressing KIR2DS1 are not negatively selected by the 
presence of its cognate ligand HLA-C2, but KIR2DS1+ NK cells negative for 
inhibitory HLA class I receptors, were hyporesponsive in HLA-C2+ individuals, 
thus ensuring tolerance. KIR2DS1 receptor is however functional in HLA-C2+ 
individuals, and KIR2DS1+ NK cells can be stimulated via cytokines, and 
possibly via ligands that remain to be discovered. 
 
• Yellow fever virus vaccination results in activation and proliferation of 
predominantly less differentiated CD57- NK cells, on day 6-10 post 
vaccination. The immune response leads to in vivo priming of both educated 
and non-educated NK cells, resulting in a transient increased responsiveness to 
target cell stimulation. Moreover, no changes in KIR repertoire following 
vaccination were detected.  
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Outlook 
At the time of writing, “big data” is causing a commotion in the media, with too much 
personal information being collected by authorities including the American NSA. 
 
In science, we have seen the same revolution towards big data. However, in contrast to 
the negative sentiments this causes for society in general, for us scientists it creates 
great opportunities. Although daunting at first, having access to big data about e.g. a 
particular cell type like an ILC, with information about its phenotype, genotype, 
transcriptome, KIRome(!) et cetera, is a blessing. It shifts some of our focus in research 
from generating data, to analyzing and interpreting data. Interpreting data means 
answering scientific questions, and with bigger data, we can dare to ask bigger 
questions.  
 
In contemporary immunology, big data is represented by for instance multiparameter 
cytometry, including flow cytometry and mass cytometry (CyTOF). With access to 
such sophisticated high-dimensional analysis tools, more and more features of ILCs can 
be studied on a single-cell level. Such possibilities will allow even deeper dissections of 
e.g. NK cell receptor functions and mechanisms, as well as the developmental 
relationships between immune cells. I wish to highlight two areas of research that are 
likely to be touched by these techniques, and that I hope to contribute to by asking and 
(to some degree) answering big questions. 
 
Future investigations into the development and differentiation of immune cells during 
fetal development will likely reveal more dissimilarities between cells in the womb, 
and cells with seemingly identical phenotypes after birth. In line with what we 
hypothesized in Paper II, such findings will shed light on why fetal cells look and 
behave like they do. The answer to such a “why” question will be reached only by 
interpreting our results through the “lens of evolution”. This will hopefully let us grasp 
the pressures from natural selection that have resulted in the unique evolutionary 
adaptations of the fetal immune system. 
As discussed in Paper III, the establishment of a fetal-maternal interface in human 
pregnancy is a fascinating area of research. By elucidating the roles that maternal and 
fetal cells play in the early stages of pregnancy, and learning to monitor and possibly 
manipulate them, this research can be beneficial for the individual woman, her 
developing fetus, and for society in terms of healthcare costs.  
 
From an academic standpoint, the unique physiological adaptations in humans are 
enticing, and by collecting big data about its components, i.e. the cells, we can find the 
big answers to how the cells interact during pregnancy, and how they have evolved. 
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